prednisone has been researched along with Graft-Versus-Host Disease in 200 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase III study to test the hypothesis that initial therapy with "lower dose" prednisone is effective and safe for patients with newly diagnosed acute graft-versus-host disease." | 9.20 | Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. ( Boeckh, M; Carpenter, PA; Flowers, ME; Furlong, T; Green, ML; Martin, PJ; McDonald, GB; Mielcarek, M; Storb, R; Storer, BE, 2015) |
| "We conducted a phase II trial in 19 chronic graft-versus-host disease (cGVHD) patients with rapamycin, calcineurin inhibitors, and prednisone with the goals of controlling cGVHD, reducing prednisone use, and defining the safety of this regimen." | 9.11 | Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. ( Blume, KG; Brown, J; Chao, NJ; Johnston, LJ; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ, 2005) |
| "Results of previous studies have suggested that transplantation-related mortality among patients with chronic graft-versus-host disease (GVHD) may be reduced by combined treatment with cyclosporine (CSP) and prednisone rather than by prednisone alone." | 9.10 | Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2002) |
| "In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD)." | 9.09 | Thalidomide for treatment of patients with chronic graft-versus-host disease. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2000) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 9.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| " In a randomized study we explored whether prednisone administered from day 0 through 35 along with methotrexate/cyclosporine could improve prevention of acute graft-versus-host disease (GVHD)." | 9.06 | What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? ( Anasetti, C; Appelbaum, FR; Beatty, P; Doney, K; Martin, P; Pepe, M; Stewart, P; Storb, R; Sullivan, KM; Witherspoon, R, 1990) |
| "We hypothesized that initial treatment of acute graft-versus-host disease (GVHD) with low-dose glucocorticoids (prednisone-equivalent dose of 1 mg/kg per day) instead of standard-dose glucocorticoids (prednisone-equivalent dose of 2 mg/kg per day) does not compromise major transplantation outcomes." | 7.75 | Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. ( Appelbaum, FR; Boeckh, M; Carpenter, PA; Deeg, HJ; Doney, K; Flowers, ME; Furlong, T; Lee, S; Marr, KA; Martin, PJ; McDonald, GB; Mielcarek, M; Nash, RA; Storb, R; Storer, BE, 2009) |
| " We report here the results of a retrospective study to review the outcomes of low-dose MTX used for treatment of refractory chronic graft-versus-host disease GVHD, with the goal of reducing the amount of prednisone needed to control the disease." | 7.73 | Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. ( Carpenter, P; Flowers, ME; Funke, VA; Giaccone, L; Hooper, H; Martin, P; Moravec, C; Storb, R, 2005) |
| "To determine the effect of two different graft-versus-host disease (GVHD) prophylactic regimens--cyclosporine with short course of methotrexate (CYA-MTX) and cyclosporine with prednisone (CYA-PRED)--on the incidence of chronic GVHD (cGVHD), we retrospectively reviewed the outcomes of 196 consecutive allogeneic related blood and marrow transplants performed at our institution utilizing one of these regimens." | 7.71 | Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. ( Chen, MG; Gastineau, DA; Gertz, MA; Harmsen, WS; Inwards, DJ; Kumar, S; Lacy, MQ; Litzow, MR; Tefferi, A, 2001) |
| "Cyclosporine and prednisone were administered as graft-versus-host disease (GVHD) prophylaxis to nine patients undergoing marrow transplant from HLA matched, unrelated donors." | 7.68 | rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis. ( Anasetti, C; Bianco, JA; Hasen, J; Nemunaitis, J; Singer, JW, 1993) |
| "A new regimen for prevention of acute graft-versus-host disease (GvHD)--OKT3 (murine monoclonal anti-pan-T antibody), prednisone and methotrexate (OKT3-pred-MTX)--was compared with the Minnesota standard regimen--antithymocyte globulin, prednisone and methotrexate (ATG-pred-MTX)--for adverse effects, effect on incidence of acute GvHD, and survival at 1 year post-transplant." | 7.67 | Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation. ( Filipovich, AH; Goldman, A; Goldstein, G; Kersey, JH; Krawczak, CL; McGlave, P; Ramsay, NK, 1985) |
| " Posttransplant immunosuppression consisting of methotrexate (MTX), antithymocyte globulin (ATG), and prednisone was used in an effort to decrease graft-versus-host disease (GVHD)." | 7.67 | Allogeneic bone marrow transplantation with related donors other than HLA MLC-matched siblings, and the use of antithymocyte globulin, prednisone, and methotrexate for prophylaxis of graft-versus-host disease. ( Arthur, DC; Filipovich, AH; Kersey, JH; Kim, T; McGlave, P; Ramsay, NK, 1985) |
| "Imatinib mesylate is a multikinase inhibitor of several signaling pathways implicated in skin fibrosis with in vitro antifibrotic activity." | 6.80 | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. ( Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L, 2015) |
| " Prednisone was dosed at ." | 6.79 | A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. ( Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ, 2014) |
| " Further investigation and formal studies of the dose-response relationships and kinetics of steroid administration may lead to improvement in the management of acute GVHD." | 6.67 | Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. ( Blazar, BL; Filipovich, AH; Hings, IM; Kersey, JH; McGlave, PB; Miller, WJ; Ramsay, NK; Weisdorf, DJ, 1993) |
| "Treatment with prednisone alone results in fewer infections and better survival than prednisone and azathioprine in standard-risk chronic GVHD." | 6.66 | Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. ( Appelbaum, FR; Dahlberg, S; Deeg, HJ; Doney, KC; Flournoy, N; Sanders, JE; Storb, R; Sullivan, KM; Weiden, P; Witherspoon, RP, 1988) |
| "We observed a rapid decrease in minimal residual disease on molecular assessment with an MMR of P190-BCR-ABL/ABL = 0." | 5.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
| "Sirolimus was initiated at a median of 9 (1-255) days after glucocorticoid initiation." | 5.36 | Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. ( Alsina, M; Anasetti, C; Ayala, E; Bookout, R; Fernandez, HF; Field, T; Greene, J; Hoda, D; Janssen, W; Kharfan-Dabaja, MA; Kim, J; Ochoa-Bayona, JL; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Salgado-Vila, N, 2010) |
| "We conducted a phase III study to test the hypothesis that initial therapy with "lower dose" prednisone is effective and safe for patients with newly diagnosed acute graft-versus-host disease." | 5.20 | Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. ( Boeckh, M; Carpenter, PA; Flowers, ME; Furlong, T; Green, ML; Martin, PJ; McDonald, GB; Mielcarek, M; Storb, R; Storer, BE, 2015) |
| "To define high-risk acute graft-versus-host disease (GVHD) at onset, we examined the initial GVHD stage and grade of 864 patients at the University of Minnesota who received uniform therapy with prednisone 60 mg/m(2) per d." | 5.16 | What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. ( DeFor, TE; MacMillan, ML; Weisdorf, DJ, 2012) |
| "We conducted a phase II trial in 19 chronic graft-versus-host disease (cGVHD) patients with rapamycin, calcineurin inhibitors, and prednisone with the goals of controlling cGVHD, reducing prednisone use, and defining the safety of this regimen." | 5.11 | Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. ( Blume, KG; Brown, J; Chao, NJ; Johnston, LJ; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ, 2005) |
| "Results of previous studies have suggested that transplantation-related mortality among patients with chronic graft-versus-host disease (GVHD) may be reduced by combined treatment with cyclosporine (CSP) and prednisone rather than by prednisone alone." | 5.10 | Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2002) |
| "We have previously demonstrated a decrease in the incidence of acute graft-versus-host disease (GVHD) with the addition of methotrexate (MTX) to cyclosporine (CSP) and prednisone (PSE) chemotherapy in patients with leukemia." | 5.09 | Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. ( Amylon, MD; Bluzme, KG; Chao, NJ; Forman, SJ; Fung, H; Hu, WW; Jain, M; Johnston, LJ; Kashyap, A; Kohler, S; Krishnan, A; Long, GD; Molina, A; Nademanee, AP; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, P; Rodriguez, R; Snyder, DS; Spielberger, R; Stein, A; Stockerl-Goldstein, KE; Tierney, DK; Wong, RM, 2000) |
| "In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD)." | 5.09 | Thalidomide for treatment of patients with chronic graft-versus-host disease. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2000) |
| "Nine adult patients 31-47 (median 39) years of age treated with prednisone and cyclosporin A (CsA) for chronic graft-versus-host disease (GVHD) were evaluated for biochemical factors associated with skeletal turnover at initiation of immunosuppressive therapy (3 months after marrow transplant) and 9 months later (follow-up)." | 5.08 | Bone density loss during treatment of chronic GVHD. ( Aker, SN; Bruemmer, B; Chesnut, CH; Lenssen, PS; Sanders, J; Stern, JM; Sullivan, KM, 1996) |
| " Prophylaxis against graft-versus-host disease (GVHD) consisted of cyclosporine alone for 5 patients and CSA plus methotrexate for 11 patients." | 5.08 | Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. ( Appelbaum, FR; Bensinger, WI; Benyunes, M; Buckner, CD; Clift, R; Demirer, T; Lee, M; Martin, P; Rowley, S; Schiller, G; Shannon-Dorcy, K; Storb, R, 1996) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 5.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| " Cyclosporine and methotrexate were used for prophylaxis against acute graft-versus-host disease (GVHD)." | 5.06 | Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. ( Anasetti, C; Appelbaum, FR; Bearman, SI; Beatty, P; Bensinger, WI; Buckner, CD; Clift, RA; Doney, K; Fisher, LD; Petersen, FB, 1990) |
| " In a randomized study we explored whether prednisone administered from day 0 through 35 along with methotrexate/cyclosporine could improve prevention of acute graft-versus-host disease (GVHD)." | 5.06 | What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? ( Anasetti, C; Appelbaum, FR; Beatty, P; Doney, K; Martin, P; Pepe, M; Stewart, P; Storb, R; Sullivan, KM; Witherspoon, R, 1990) |
| "Prior clinical trials largely considered prednisone 1 mg/kg per day with or without calcineurin inhibitor as standard initial therapy for chronic graft-versus-host disease (cGVHD), but uncertainty remains regarding the extent of practice variation and whether this affects subsequent outcomes." | 4.02 | Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. ( Alousi, A; Arai, S; Arora, M; Carpenter, PA; Chen, GL; Cutler, C; Flowers, MED; Hamilton, BK; Jacobsohn, D; Kitko, CL; Lee, SJ; Martin, PJ; Onstad, L; Pidala, J; Pusic, I; White, J, 2021) |
| " Amlodipine was started for steroid-induced hypertension; 11 days after its initiation, alanine aminotransferase and aspartate aminotransferase peaked at 630 and 421 IU/L, respectively." | 3.81 | Possible amlodipine-induced hepatotoxicity after stem cell transplant. ( Hammerstrom, AE, 2015) |
| "We hypothesized that initial treatment of acute graft-versus-host disease (GVHD) with low-dose glucocorticoids (prednisone-equivalent dose of 1 mg/kg per day) instead of standard-dose glucocorticoids (prednisone-equivalent dose of 2 mg/kg per day) does not compromise major transplantation outcomes." | 3.75 | Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. ( Appelbaum, FR; Boeckh, M; Carpenter, PA; Deeg, HJ; Doney, K; Flowers, ME; Furlong, T; Lee, S; Marr, KA; Martin, PJ; McDonald, GB; Mielcarek, M; Nash, RA; Storb, R; Storer, BE, 2009) |
| " We report here the results of a retrospective study to review the outcomes of low-dose MTX used for treatment of refractory chronic graft-versus-host disease GVHD, with the goal of reducing the amount of prednisone needed to control the disease." | 3.73 | Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. ( Carpenter, P; Flowers, ME; Funke, VA; Giaccone, L; Hooper, H; Martin, P; Moravec, C; Storb, R, 2005) |
| " Therapy with oral prednisone easily controlled her skin rash but she had profuse diarrhea that did not respond to high dose intravenous corticosteroids and denileukin diftitox." | 3.73 | Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. ( Bierbaum, W; Hamadani, M; Maqbool, F; Selby, G; Tfayli, A, 2006) |
| " The immunosuppressive drugs prednisone and cyclosporin A (CsA) are routinely used during HSCT to prevent or treat graft-versus-host disease (GVHD) or to inhibit antibody-mediated inflammation." | 3.72 | Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth? ( D'Costa, S; Hurwitz, JL; Slobod, KS, 2003) |
| "To determine the effect of two different graft-versus-host disease (GVHD) prophylactic regimens--cyclosporine with short course of methotrexate (CYA-MTX) and cyclosporine with prednisone (CYA-PRED)--on the incidence of chronic GVHD (cGVHD), we retrospectively reviewed the outcomes of 196 consecutive allogeneic related blood and marrow transplants performed at our institution utilizing one of these regimens." | 3.71 | Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. ( Chen, MG; Gastineau, DA; Gertz, MA; Harmsen, WS; Inwards, DJ; Kumar, S; Lacy, MQ; Litzow, MR; Tefferi, A, 2001) |
| "We report a patient who developed recurrent acute inflammatory demyelinating polyradiculitis (AIDP) receiving immunosuppressive treatment with cyclosporin and prednisone for secondary chronic graft versus host disease (GVHD) following allogeneic bone marrow transplantation (BMT) from an unrelated donor for chronic myelogenous leukemia (CML)." | 3.69 | Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. ( Beelen, DW; Liedtke, W; Quabeck, K; Schaefer, UW; Straeten, V, 1994) |
| " Graft-versus-host disease (GVHD) prophylaxis included cyclosporin A and prednisone." | 3.69 | Bone marrow transplantation in Fanconi anemia using matched sibling donors. ( DeLaat, C; Desantes, K; Friedman, DJ; Kohli-Kumar, M; Masterson, M; Morris, C; Mueller, R; Sambrano, J; Shahidi, NT; Yanik, G, 1994) |
| "Cyclosporine and prednisone were administered as graft-versus-host disease (GVHD) prophylaxis to nine patients undergoing marrow transplant from HLA matched, unrelated donors." | 3.68 | rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis. ( Anasetti, C; Bianco, JA; Hasen, J; Nemunaitis, J; Singer, JW, 1993) |
| " Fifty-eight patients were prepared for transplantation with a combination of cyclophosphamide and fractionated total body irradiation (FTBI) and received acute graft-versus-host disease (GVHD) prophylaxis consisting of methotrexate alone or in combination with cyclosporine, prednisone, or antithymocyte globulin (ATG)." | 3.68 | Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. ( Ash, R; Beatty, P; Hows, JM; McGlave, PB, 1990) |
| " The presence of acute graft-versus-host disease (GVHD) at the time of endoscopy and the use of prednisone prior to endoscopy were considered possible risk factors for the development of bacteremia." | 3.68 | Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients. ( Applebaum, FR; Bianco, JA; Higano, C; McDonald, GB; Pepe, MS; Singer, JW, 1990) |
| " The prevention of graft-versus-host disease (GVHD) was undertaken with methotrexate (MTX), MTX plus antilymphocytic gammaglobulin plus prednisone (MTX + ALT + P), and elimination of the T-lymphocytes of the donor's bone marrow with the monoclonal antibody CAMPATH-1." | 3.67 | [Prevention of acute graft versus host disease using 3 prophylactic schemes]. ( Bello, C; Bureo, E; Conde, E; Cuadrado, MA; Garijo, J; Hermosa, V; Iriondo, A; Pastor, JM; Recio, M; Richard, C, 1989) |
| " Posttransplant immunosuppression consisting of methotrexate (MTX), antithymocyte globulin (ATG), and prednisone was used in an effort to decrease graft-versus-host disease (GVHD)." | 3.67 | Allogeneic bone marrow transplantation with related donors other than HLA MLC-matched siblings, and the use of antithymocyte globulin, prednisone, and methotrexate for prophylaxis of graft-versus-host disease. ( Arthur, DC; Filipovich, AH; Kersey, JH; Kim, T; McGlave, P; Ramsay, NK, 1985) |
| "A new regimen for prevention of acute graft-versus-host disease (GvHD)--OKT3 (murine monoclonal anti-pan-T antibody), prednisone and methotrexate (OKT3-pred-MTX)--was compared with the Minnesota standard regimen--antithymocyte globulin, prednisone and methotrexate (ATG-pred-MTX)--for adverse effects, effect on incidence of acute GvHD, and survival at 1 year post-transplant." | 3.67 | Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation. ( Filipovich, AH; Goldman, A; Goldstein, G; Kersey, JH; Krawczak, CL; McGlave, P; Ramsay, NK, 1985) |
| "Sirolimus was associated with reduced steroid exposure and hyperglycemia, reduced grade 2 to 3 infections, improvement in immune suppression discontinuation and patient-reported quality of life, and increased risk for thrombotic microangiopathy." | 2.94 | Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. ( Alousi, AM; Anasetti, C; Antin, JH; Bolaños-Meade, J; Chhabra, S; Dawson, P; Efebera, YA; Ferrara, JLM; Hamadani, M; Holtan, SG; Horowitz, MM; Howard, A; Jagasia, M; Leifer, ES; Levine, JE; Logan, BR; MacMillan, ML; Martens, M; Mielcarek, M; Pidala, J; Pritchard, TS; Pusic, I, 2020) |
| " Ofatumumab in combination with prednisone is safe and a phase II examination of efficacy is ongoing." | 2.80 | Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. ( Alsina, M; Anasetti, C; Ayala, E; Betts, BC; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Locke, FL; Mishra, A; Nishihori, T; Ochoa-Bayona, L; Perez, L; Pidala, J; Riches, M, 2015) |
| "Imatinib mesylate is a multikinase inhibitor of several signaling pathways implicated in skin fibrosis with in vitro antifibrotic activity." | 2.80 | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. ( Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L, 2015) |
| " Prednisone was dosed at ." | 2.79 | A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. ( Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ, 2014) |
| "Three patients had grade 3 infections." | 2.71 | Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. ( Dührsen, U; Kasper, C; Müller-Beissenhirtz, H; Nückel, H, 2005) |
| " Further investigation and formal studies of the dose-response relationships and kinetics of steroid administration may lead to improvement in the management of acute GVHD." | 2.67 | Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. ( Blazar, BL; Filipovich, AH; Hings, IM; Kersey, JH; McGlave, PB; Miller, WJ; Ramsay, NK; Weisdorf, DJ, 1993) |
| "Initial treatment and relapse therapy were similar in all patients according to the BFM- and CoALL-protocols (front line: 38 patients according to BFM-protocols and 13 patients according to CoALL-protocols; relapse: 12 patients in study ALL-REZ-BFM 83, 17 in ALL-REZ-BFM 85, 20 in ALL-REZ-BFM 87, and two in ALL-REZ-BFM 90)." | 2.67 | Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. ( Bender-Götze, C; Dopfer, R; Ebell, W; Ehninger, G; Friedrich, W; Gadner, H; Henze, G; Klingebiel, T; Peters, C; Riehm, H, 1991) |
| "Treatment with prednisone alone results in fewer infections and better survival than prednisone and azathioprine in standard-risk chronic GVHD." | 2.66 | Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. ( Appelbaum, FR; Dahlberg, S; Deeg, HJ; Doney, KC; Flournoy, N; Sanders, JE; Storb, R; Sullivan, KM; Weiden, P; Witherspoon, RP, 1988) |
| " Optimizing prednisone (and prednisolone) dosing by measuring their concentrations and calculating their pharmacokinetic parameters will allow for personalized treatments for patients, producing more effective and safer treatments for GVHD." | 2.44 | Simultaneous Determination of Prednisone and Prednisolone in Serum by Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry. ( Carlow, DC; Schofield, RC; Scordo, M; Shah, G, 2024) |
| "Evans syndrome is a rare disorder characterized by combined autoimmune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA)." | 2.41 | Allogeneic stem cell transplantation for Evans syndrome. ( Burt, RK; Miranda, M; Oyama, Y; Papadopoulos, EB; Traynor, AE, 2001) |
| "Polymyositis is a rarely reported complication of chronic graft-versus-host disease (GVHD) with only 8 cases described in the literature." | 2.39 | Polymyositis as a manifestation of chronic graft-versus-host disease. ( Ben-Ezra, J; Blume, KG; Chao, NJ; Forman, SJ; Greffe, BS; Kashyap, A; Linker, CA; Molina, A; Nademanee, A; Niland, JC; O'Donnell, MR; Openshaw, H; Parker, P; Planas, I; Sheibani, K; Slatkin, N; Smith, EP; Snyder, DS; Spielberger, R; Stein, AS; Stepan, DE, 1996) |
| " The changes in their pulmonary function for 12 months following treatment with rituximab were followed, along with other intervention performed and daily average dosing of prednisone." | 1.46 | Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease. ( Abhyankar, S; Brownback, KR; Ganguly, S; McGuirk, JP; Streiler, C; Thomas, LA, 2017) |
| "We observed a rapid decrease in minimal residual disease on molecular assessment with an MMR of P190-BCR-ABL/ABL = 0." | 1.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
| "Sirolimus was initiated at a median of 9 (1-255) days after glucocorticoid initiation." | 1.36 | Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. ( Alsina, M; Anasetti, C; Ayala, E; Bookout, R; Fernandez, HF; Field, T; Greene, J; Hoda, D; Janssen, W; Kharfan-Dabaja, MA; Kim, J; Ochoa-Bayona, JL; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Salgado-Vila, N, 2010) |
| "Treatment with prednisone resulted in decreased CD86 expression in marrow (P=0." | 1.35 | Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. ( Arpinati, M; Baccarani, M; Chirumbolo, G; Marzocchi, G; Rondelli, D, 2008) |
| "Polymyositis is a rare manifestation of chronic GVHD after donor lymphocyte infusion (DLI)." | 1.35 | Polymyositis and myocarditis after donor lymphocyte infusion. ( Ahn, JS; Bae, WK; Cho, SH; Chung, IJ; Juhng, SW; Kim, HJ; Kim, YK; Lee, JJ; Shim, HJ; Yang, DH, 2009) |
| "Polymyositis is an uncommon manifestation as a complication of chronic graft-versus-host disease (GVHD)." | 1.35 | [A case of chronic graft-versus-host disease presenting with polymyositis]. ( Inoue, M; Kitazono, T; Maeda, A; Okazaki, T; Ozaki, S; Shibata, T, 2009) |
| "We conclude that women with breast cancer or hematologic malignancy are more likely to develop GI GVHD after autologous transplantation, and that treatment with prednisone was effective." | 1.33 | Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. ( Adams, KM; Bensinger, W; Flowers, ME; Gooley, TA; Hockenbery, DM; Holmberg, L; Kikuchi, K; McDonald, GB; Schoch, HG, 2006) |
| "Tacrolimus (FK506) is a potent macrolide lactone immunosuppressant that is used in the prevention of solid organ rejection." | 1.31 | Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment. ( Ilan, Y; Menachem, Y; Nagler, A, 2001) |
| "Pancreatitis has been described as an infrequent complication of marrow transplantation." | 1.30 | Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis. ( Gooley, T; Hackman, RC; Ko, CW; Lee, SP; McDonald, GB; Myerson, D; Sale, GE; Schoch, HG; Shulman, HM, 1997) |
| "In conclusion, avascular necrosis of bone is a frequent late complication of allogeneic bone marrow transplantation causing significant morbidity and requiring replacement surgery in one-third of affected patients." | 1.29 | Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. ( Devergie, A; Esperou Bourdeau, H; Frija, J; Gluckman, E; Ribaud, P; Sedel, L; Sélimi, F; Socié, G, 1994) |
| "While bronchiolitis obliterans has been reported following allogeneic transplant, BOOP has not previously been reported in this setting." | 1.28 | Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation. ( Cizek, G; Devine, SM; Geller, RB; Hertz, M; Jessurun, J; O'Toole, K; Thirman, MJ, 1992) |
| "Prednisone treatment led to 10 of 41 (24%) patients improving, while secondary therapy with ATG led to four of 21 (19%) improving." | 1.28 | Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. ( Blazar, BR; Filipovich, AH; Kersey, JH; McGlave, PB; Miller, WJ; Ramsay, NK; Roy, J; Weisdorf, DJ, 1992) |
| "Avascular necrosis of bone is a frequent late complication of bone marrow transplantation, causing significant morbidity and often requiring surgery; diagnosis using conventional imaging techniques may be difficult and treatment remains inadequate." | 1.28 | Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. ( Enright, H; Haake, R; Weisdorf, D, 1990) |
| "There was nothing to suggest aspiration pneumonia." | 1.28 | Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease. ( Atkinson, K; Biggs, J; Bryant, D; Delprado, W, 1989) |
| "Thalidomide treatment was successful in the majority of animals (16 of 18)." | 1.28 | Therapy of chronic graft-v-host disease in a rat model. ( Friedman, KJ; Hess, AD; Santos, GW; Vogelsang, GB, 1989) |
| "Eight patients with disseminated Hodgkin's disease resistant to MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy were treated with high-dose chemoradiotherapy and marrow transplantation from an HLA-identical sibling." | 1.27 | Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. ( Appelbaum, FR; Buckner, CD; Clift, RA; Deeg, HJ; Neiman, PE; Sanders, JE; Stewart, P; Storb, R; Sullivan, KM; Thomas, ED, 1985) |
| "Mediastinal lipomatosis has been described in adults and is a well recognized cause of mediastinal enlargement." | 1.27 | Mediastinal lipomatosis: a complication of high dose steroid therapy in children. ( Katz, JA; Shukla, LW; Wagner, ML, 1988) |
| " Although one patient subsequently required chronic dialysis, reduction of cyclosporine dosage from a mean of 5." | 1.27 | Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. ( Bahnson, HT; Bernstein, RL; Egel, JW; Greenberg, A; Griffith, BP; Hardesty, RL; Hastillo, A; Hess, ML; Puschett, JB; Thompson, ME, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (14.50) | 18.7374 |
| 1990's | 39 (19.50) | 18.2507 |
| 2000's | 70 (35.00) | 29.6817 |
| 2010's | 49 (24.50) | 24.3611 |
| 2020's | 13 (6.50) | 2.80 |
| Authors | Studies |
|---|---|
| Pidala, J | 6 |
| Onstad, L | 1 |
| Martin, PJ | 16 |
| Hamilton, BK | 1 |
| Cutler, C | 3 |
| Kitko, CL | 2 |
| Carpenter, PA | 10 |
| Chen, GL | 1 |
| Arora, M | 4 |
| Flowers, MED | 2 |
| Arai, S | 2 |
| Alousi, A | 1 |
| White, J | 5 |
| Jacobsohn, D | 1 |
| Pusic, I | 2 |
| Lee, SJ | 6 |
| Lazaryan, A | 1 |
| Lee, S | 2 |
| Kim, J | 4 |
| Betts, BC | 2 |
| Khimani, F | 1 |
| Nishihori, T | 3 |
| Bejanyan, N | 1 |
| Liu, H | 1 |
| Kharfan-Dabaja, MA | 4 |
| Locke, FL | 2 |
| Gonzalez, R | 1 |
| Jain, MD | 1 |
| Davila, ML | 1 |
| Perez, LE | 1 |
| Mishra, A | 2 |
| Perez Perez, A | 1 |
| Balke, K | 1 |
| Ayala, E | 3 |
| Ochoa, L | 1 |
| Castaneda Puglianini, O | 1 |
| Faramand, R | 1 |
| Alsina, M | 3 |
| Elmariah, H | 1 |
| Nieder, ML | 1 |
| Fernandez, H | 2 |
| Anasetti, C | 14 |
| Pidala, JA | 1 |
| Heckmann, JM | 1 |
| Elemary, M | 4 |
| Linn, SM | 5 |
| Novitzky-Basso, I | 5 |
| Culos, S | 4 |
| Tan, SK | 3 |
| Kelly, K | 4 |
| Deotare, U | 4 |
| Xenocostas, A | 4 |
| Hamad, N | 4 |
| Law, A | 5 |
| Kumar, R | 5 |
| Kim, DDH | 6 |
| Tan, S | 1 |
| Mattsson, J | 2 |
| Patriquin, C | 1 |
| Chiarello, C | 1 |
| Pasic, I | 1 |
| Lam, W | 1 |
| Michelis, FV | 2 |
| Gerbitz, A | 2 |
| Viswabandya, A | 2 |
| Lipton, J | 2 |
| Barth, D | 1 |
| Schofield, RC | 1 |
| Scordo, M | 1 |
| Shah, G | 1 |
| Carlow, DC | 1 |
| MacMillan, ML | 6 |
| Holtan, SG | 2 |
| Rashidi, A | 1 |
| DeFor, TE | 4 |
| Blazar, BR | 7 |
| Weisdorf, DJ | 8 |
| Hamadani, M | 2 |
| Dawson, P | 1 |
| Martens, M | 1 |
| Alousi, AM | 2 |
| Jagasia, M | 4 |
| Efebera, YA | 1 |
| Chhabra, S | 1 |
| Ferrara, JLM | 1 |
| Levine, JE | 2 |
| Mielcarek, M | 4 |
| Antin, JH | 5 |
| Bolaños-Meade, J | 2 |
| Howard, A | 1 |
| Logan, BR | 2 |
| Leifer, ES | 1 |
| Pritchard, TS | 1 |
| Horowitz, MM | 2 |
| Hogan, JJ | 1 |
| Mohty, M | 2 |
| Holler, E | 3 |
| Jenq, R | 1 |
| Malard, F | 1 |
| Martin, P | 4 |
| Socié, G | 4 |
| Zeiser, R | 1 |
| Montoro, J | 1 |
| Chorão, P | 1 |
| Quintero, A | 1 |
| Roca, J | 1 |
| Guerreiro, M | 1 |
| Balaguer-Roselló, A | 1 |
| Krüger, WH | 1 |
| Hirt, C | 1 |
| Basara, N | 1 |
| Sayer, HG | 1 |
| Behre, G | 1 |
| Fischer, T | 1 |
| Grobe, N | 1 |
| Maschmeyer, G | 1 |
| Neumann, T | 1 |
| Schneidewind, L | 1 |
| Niederwieser, D | 3 |
| Dölken, G | 1 |
| Schmidt, CA | 1 |
| Storer, BE | 5 |
| Inamoto, Y | 2 |
| Palmer, J | 1 |
| Cutler, CS | 2 |
| Li, Z | 1 |
| Wang, Y | 2 |
| Wang, J | 3 |
| Zhang, J | 2 |
| Wang, Z | 2 |
| Petrungaro, A | 1 |
| Gentile, M | 1 |
| Mazzone, C | 1 |
| Greco, R | 1 |
| Uccello, G | 1 |
| Recchia, AG | 1 |
| De Stefano, L | 1 |
| Bossio, S | 1 |
| Palummo, A | 1 |
| Morelli, R | 1 |
| Musolino, C | 1 |
| Morabito, F | 1 |
| Vigna, E | 1 |
| Brownback, KR | 1 |
| Thomas, LA | 1 |
| McGuirk, JP | 1 |
| Ganguly, S | 1 |
| Streiler, C | 1 |
| Abhyankar, S | 2 |
| Tawfik, P | 1 |
| Arndt, P | 1 |
| Uhm, J | 1 |
| Shin, E | 1 |
| Thyagu, S | 1 |
| Lipton, JH | 2 |
| Messner, HA | 2 |
| Kaffenberger, J | 1 |
| Helm, K | 1 |
| Miller, J | 1 |
| Nahas, MR | 1 |
| Soiffer, RJ | 2 |
| Kim, HT | 3 |
| Alyea, EP | 2 |
| Arnason, J | 1 |
| Joyce, R | 1 |
| Ho, VT | 3 |
| Stroopinsky, D | 1 |
| Li, S | 1 |
| Levine, JD | 1 |
| McMasters, M | 1 |
| Jain, S | 1 |
| Hamdan, A | 1 |
| Tzachanis, D | 1 |
| Bryant, MP | 1 |
| Logan, EK | 1 |
| Bazemore, J | 1 |
| Stewart, J | 1 |
| Joyce, A | 1 |
| Stephenson, S | 1 |
| Washington, A | 1 |
| Cole, L | 1 |
| Pyzer, A | 1 |
| Leaf, RK | 1 |
| Avigan, DE | 1 |
| Rosenblatt, J | 1 |
| Richet, C | 1 |
| Huynh, A | 1 |
| Dimeglio, C | 1 |
| Borel, C | 1 |
| Lepage, B | 1 |
| Boulinguez, S | 1 |
| Marguery, MC | 1 |
| Paul, C | 1 |
| Bulai Livideanu, C | 1 |
| Lunning, MA | 1 |
| Moskowitz, AJ | 1 |
| Horwitz, S | 1 |
| Chalkias, S | 1 |
| Mackenzie, MR | 1 |
| Gay, C | 1 |
| Dooley, C | 1 |
| Marty, FM | 1 |
| Moss, RB | 1 |
| Li, T | 1 |
| Routh, RL | 1 |
| Walsh, SR | 1 |
| Tan, CS | 1 |
| Kletzel, M | 1 |
| Powers, K | 1 |
| Hayes, M | 1 |
| Takashima, S | 1 |
| Eto, T | 1 |
| Shiratsuchi, M | 1 |
| Hidaka, M | 1 |
| Mori, Y | 1 |
| Kato, K | 1 |
| Kamezaki, K | 1 |
| Oku, S | 1 |
| Henzan, H | 1 |
| Takase, K | 1 |
| Matsushima, T | 2 |
| Takenaka, K | 1 |
| Iwasaki, H | 1 |
| Miyamoto, T | 1 |
| Akashi, K | 1 |
| Teshima, T | 1 |
| Koga, Y | 1 |
| Takada, H | 1 |
| Suminoe, A | 1 |
| Ohga, S | 1 |
| Hara, T | 1 |
| Herrera, AF | 1 |
| Bindra, B | 1 |
| Jones, KT | 1 |
| Armand, P | 1 |
| Nikiforow, S | 1 |
| Ritz, J | 2 |
| Koreth, J | 1 |
| Barowski, K | 1 |
| Carter, SL | 1 |
| Goldstein, SC | 1 |
| Hexner, EO | 1 |
| Mendizabal, AM | 1 |
| Nakamura, R | 1 |
| Pasquini, MC | 1 |
| Westervelt, P | 1 |
| Hammerstrom, AE | 1 |
| de Lima, M | 1 |
| Nishimoto, M | 1 |
| Nakamae, H | 1 |
| Koh, H | 1 |
| Nakamae, M | 1 |
| Hirose, A | 1 |
| Hayashi, Y | 1 |
| Nakashima, Y | 1 |
| Nakane, T | 1 |
| Hino, M | 1 |
| Furlong, T | 3 |
| Green, ML | 1 |
| McDonald, GB | 12 |
| Flowers, ME | 10 |
| Storb, R | 18 |
| Boeckh, M | 2 |
| Baird, K | 1 |
| Comis, LE | 1 |
| Joe, GO | 1 |
| Steinberg, SM | 1 |
| Hakim, FT | 1 |
| Rose, JJ | 1 |
| Mitchell, SA | 1 |
| Pavletic, SZ | 2 |
| Figg, WD | 1 |
| Yao, L | 1 |
| Flanders, KC | 1 |
| Takebe, N | 1 |
| Sarantopoulos, S | 1 |
| Booher, S | 1 |
| Cowen, EW | 1 |
| Fernandez, HF | 2 |
| Field, T | 3 |
| Ochoa-Bayona, L | 1 |
| Perez, L | 3 |
| Riches, M | 1 |
| Sorenson, E | 1 |
| McAndrew, R | 1 |
| Patel, V | 1 |
| Logan, AC | 1 |
| Koo, J | 1 |
| Levin, E | 1 |
| Te Boome, LC | 1 |
| Mansilla, C | 1 |
| van der Wagen, LE | 1 |
| Lindemans, CA | 1 |
| Petersen, EJ | 1 |
| Spierings, E | 1 |
| Thus, KA | 1 |
| Westinga, K | 1 |
| Plantinga, M | 1 |
| Bierings, M | 1 |
| Broers, AE | 1 |
| Cuijpers, ML | 1 |
| van Imhoff, GW | 1 |
| Janssen, JJ | 1 |
| Huisman, C | 1 |
| Zeerleder, S | 1 |
| Huls, G | 1 |
| Boelens, JJ | 1 |
| Wulffraat, NM | 1 |
| Slaper-Cortenbach, IC | 1 |
| Kuball, J | 1 |
| Inagaki, J | 2 |
| Kodama, Y | 1 |
| Fukano, R | 1 |
| Noguchi, M | 1 |
| Okamura, J | 2 |
| Nielson, C | 1 |
| Fraga, GR | 1 |
| Fischer, R | 1 |
| Rajpara, A | 1 |
| Hong, C | 1 |
| Tang, KS | 1 |
| Villegas, M | 1 |
| Tan, PL | 1 |
| Zou, BH | 1 |
| Zhang, Q | 1 |
| Xu, YR | 1 |
| Qiao, ZQ | 1 |
| Li, YH | 1 |
| Chen, JL | 1 |
| Hu, LD | 1 |
| Zhang, B | 1 |
| Chen, H | 1 |
| Wu, L | 1 |
| Lai, W | 1 |
| Liu, AW | 1 |
| Bateman, AC | 1 |
| Greenbaum, A | 1 |
| Garvin, K | 1 |
| Clarridge, J | 1 |
| Grim, J | 1 |
| Arpinati, M | 1 |
| Chirumbolo, G | 1 |
| Marzocchi, G | 1 |
| Baccarani, M | 1 |
| Rondelli, D | 1 |
| Kahata, K | 1 |
| Hashino, S | 1 |
| Takahata, M | 1 |
| Fujisawa, F | 1 |
| Kondo, T | 1 |
| Kobayashi, S | 1 |
| Fujita, Y | 1 |
| Shimizu, H | 1 |
| Imamura, M | 1 |
| Asaka, M | 1 |
| Deeg, HJ | 9 |
| Nash, RA | 6 |
| Doney, K | 5 |
| Marr, KA | 1 |
| Appelbaum, FR | 13 |
| Ye, CX | 1 |
| Sun, J | 1 |
| Liu, QF | 1 |
| Qu, H | 1 |
| Xu, D | 1 |
| Zhang, Y | 1 |
| Meng, FY | 1 |
| Doherty, C | 1 |
| Ulitsky, O | 1 |
| Petronic-Rosic, V | 1 |
| Okazaki, T | 1 |
| Maeda, A | 1 |
| Inoue, M | 1 |
| Kitazono, T | 1 |
| Shibata, T | 1 |
| Ozaki, S | 1 |
| Drew, DZ | 1 |
| Donohue, T | 1 |
| Ramos, C | 1 |
| Cook, L | 1 |
| Goodwin, R | 1 |
| Patronas, N | 1 |
| Arrington, D | 1 |
| Ramanathan, M | 1 |
| Childs, R | 2 |
| Ahn, JS | 1 |
| Cho, SH | 1 |
| Kim, YK | 1 |
| Yang, DH | 1 |
| Bae, WK | 1 |
| Shim, HJ | 1 |
| Lee, JJ | 1 |
| Chung, IJ | 1 |
| Juhng, SW | 1 |
| Kim, HJ | 1 |
| Hoda, D | 1 |
| Salgado-Vila, N | 1 |
| Perkins, J | 2 |
| Bookout, R | 1 |
| Ochoa-Bayona, JL | 1 |
| Raychaudhuri, J | 1 |
| Greene, J | 1 |
| Janssen, W | 1 |
| Jurkovicova, J | 1 |
| Xicoy, B | 1 |
| Bielsa, I | 1 |
| Arellano, A | 1 |
| Couriel, DR | 1 |
| Gupta, V | 1 |
| Hsu, JW | 1 |
| Maziarz, RT | 1 |
| Rowley, SD | 2 |
| Shaughnessy, PJ | 2 |
| van Besien, K | 2 |
| Weisdorf, D | 6 |
| Wolff, D | 1 |
| Ayuk, F | 1 |
| Kiani, A | 1 |
| Hildebrandt, GC | 2 |
| Vogelsang, GB | 3 |
| Elad, S | 1 |
| Lawitschka, A | 1 |
| Greinix, H | 1 |
| Said-Al-Naief, N | 1 |
| Rosebush, MS | 1 |
| Lynch, D | 1 |
| Ding, J | 1 |
| Bao, W | 1 |
| Zhao, G | 1 |
| Chen, J | 1 |
| Song, H | 1 |
| Bouazzaoui, A | 1 |
| Spacenko, E | 1 |
| Mueller, G | 1 |
| Huber, E | 1 |
| Schubert, T | 1 |
| Andreesen, R | 1 |
| Bolla, D | 1 |
| Ruhstaller, T | 1 |
| Diener, PA | 1 |
| Lang, F | 1 |
| Hornung, R | 1 |
| Lorillon, G | 1 |
| Robin, M | 1 |
| Meignin, V | 1 |
| Ribaud, P | 3 |
| Lescoeur, B | 1 |
| Gossot, D | 1 |
| Tazi, A | 1 |
| Bergeron, A | 1 |
| Jimenez-Zepeda, VH | 1 |
| Trudel, S | 1 |
| Reece, DE | 1 |
| Chen, C | 1 |
| Rabea, AM | 1 |
| Kukreti, V | 1 |
| Bisaccia, E | 2 |
| Palangio, M | 2 |
| Gonzalez, J | 2 |
| Rizzo, JD | 1 |
| Wingard, JR | 2 |
| Ballen, K | 1 |
| Curtin, PT | 1 |
| Litzow, MR | 3 |
| Nieto, Y | 1 |
| Savani, BN | 1 |
| Schriber, JR | 1 |
| Wall, DA | 1 |
| Mian, M | 1 |
| Farsad, M | 1 |
| Pescosta, N | 1 |
| Casini, M | 1 |
| Cavattoni, IM | 1 |
| Deola, S | 1 |
| Cortelazzo, S | 1 |
| Rancea, M | 1 |
| Skoetz, N | 1 |
| Monsef, I | 1 |
| Hübel, K | 1 |
| Engert, A | 1 |
| Bauer, K | 1 |
| Finke, J | 1 |
| Sandmaier, BM | 2 |
| Wagner, JE | 2 |
| Burns, LJ | 2 |
| Ramsay, NK | 6 |
| Davies, SM | 2 |
| Knox, KS | 1 |
| Behnia, M | 1 |
| Smith, LR | 1 |
| Vance, GH | 1 |
| Busk, M | 1 |
| Cummings, OW | 1 |
| Kwo, PY | 1 |
| Wilkes, DS | 1 |
| Leiter, U | 1 |
| Kaskel, P | 1 |
| Krähn, G | 1 |
| Gottlöber, P | 1 |
| Bunjes, D | 1 |
| Peter, RU | 1 |
| Kerscher, M | 1 |
| Locatelli, F | 2 |
| Zecca, M | 1 |
| Messina, C | 1 |
| Rondelli, R | 1 |
| Lanino, E | 1 |
| Sacchi, N | 1 |
| Uderzo, C | 1 |
| Fagioli, F | 1 |
| Conter, V | 2 |
| Bonetti, F | 1 |
| Favre, C | 1 |
| Porta, F | 1 |
| Giorgiani, G | 1 |
| Pession, A | 1 |
| Sanders, JE | 9 |
| Adler, KR | 1 |
| Goldberg, SL | 2 |
| D'Costa, S | 2 |
| Slobod, KS | 1 |
| Hurwitz, JL | 2 |
| SCHWARTZ, RS | 1 |
| BELDOTTI, L | 1 |
| Chohan, R | 1 |
| Vij, R | 1 |
| Adkins, D | 1 |
| Blum, W | 1 |
| Brown, R | 1 |
| Tomasson, M | 1 |
| Devine, S | 1 |
| Graubert, T | 1 |
| Goodnough, LT | 1 |
| DiPersio, JF | 1 |
| Khoury, H | 1 |
| Mandigers, CM | 1 |
| Verdonck, LF | 1 |
| Meijerink, JP | 1 |
| Dekker, AW | 1 |
| Schattenberg, AV | 1 |
| Raemaekers, JM | 1 |
| Patriarca, F | 1 |
| Skert, C | 1 |
| Sperotto, A | 1 |
| Damiani, D | 1 |
| Cerno, M | 1 |
| Geromin, A | 1 |
| Zaja, F | 1 |
| Stocchi, R | 1 |
| Prosdocimo, S | 1 |
| Fili', C | 1 |
| Fanin, R | 1 |
| Choi, I | 1 |
| Abe, Y | 1 |
| Ohtsuka, R | 1 |
| Tachikawa, Y | 1 |
| Nagasawa, E | 1 |
| Nishimura, J | 1 |
| Inaba, S | 1 |
| Nawata, H | 1 |
| Muta, K | 1 |
| Coyle, TS | 1 |
| Nam, TK | 1 |
| Camouse, MM | 1 |
| Stevens, SR | 1 |
| Baron, ED | 1 |
| Stewart, BL | 1 |
| Storer, B | 1 |
| Storek, J | 1 |
| Hansen, JA | 2 |
| Kiem, HP | 3 |
| Petersdorf, EW | 2 |
| Moravec, C | 2 |
| Morton, AJ | 1 |
| Almoallim, H | 1 |
| Patterson, AC | 1 |
| Johnston, LJ | 2 |
| Brown, J | 1 |
| Shizuru, JA | 2 |
| Stockerl-Goldstein, KE | 2 |
| Stuart, MJ | 1 |
| Blume, KG | 8 |
| Negrin, RS | 5 |
| Chao, NJ | 5 |
| Rao, PS | 1 |
| Burroughs, L | 1 |
| Leisenring, W | 4 |
| Diaconescu, R | 1 |
| Maloney, DG | 1 |
| Maris, MB | 1 |
| Chauncey, TR | 2 |
| Hegenbart, U | 1 |
| Forman, S | 1 |
| Bruno, B | 1 |
| Woolfrey, A | 2 |
| Giaccone, L | 1 |
| Carpenter, P | 1 |
| Hooper, H | 1 |
| Funke, VA | 1 |
| Müller-Beissenhirtz, H | 1 |
| Kasper, C | 1 |
| Nückel, H | 1 |
| Dührsen, U | 1 |
| Alborghetti, MR | 1 |
| Corrêa, ME | 1 |
| Adam, RL | 1 |
| Metze, K | 1 |
| Coracin, FL | 1 |
| de Souza, CA | 1 |
| Cintra, ML | 1 |
| Rodriguez, V | 1 |
| Anderson, PM | 1 |
| Trotz, BA | 1 |
| Arndt, CA | 1 |
| Allen, JA | 1 |
| Khan, SP | 1 |
| Perrotta, S | 1 |
| Conte, ML | 1 |
| La Manna, A | 1 |
| Indolfi, P | 1 |
| Rossi, F | 1 |
| Nobili, B | 1 |
| Holmberg, L | 1 |
| Kikuchi, K | 1 |
| Gooley, TA | 2 |
| Adams, KM | 1 |
| Hockenbery, DM | 5 |
| Schoch, HG | 2 |
| Bensinger, W | 2 |
| de Lavallade, H | 1 |
| Faucher, C | 1 |
| Fürst, S | 1 |
| El-Cheikh, J | 1 |
| Vey, N | 1 |
| Coso, D | 1 |
| Bouabdallah, R | 1 |
| Stoppa, AM | 1 |
| Gastaut, JA | 1 |
| Blaise, D | 1 |
| Cordonnier, C | 1 |
| Herbrecht, R | 1 |
| Milpied, N | 1 |
| Valteau-Couanet, D | 1 |
| Morgan, C | 1 |
| Wade, A | 1 |
| Leisenring, WM | 1 |
| Regan, AE | 1 |
| Aboulhosn, N | 1 |
| Stern, JM | 3 |
| Aker, SN | 2 |
| Salazar, RC | 1 |
| Miklos, D | 1 |
| Treister, N | 1 |
| Woo, SB | 1 |
| Bienfang, D | 1 |
| Klickstein, LB | 1 |
| Levin, J | 1 |
| Miller, K | 1 |
| Reynolds, C | 1 |
| Macdonell, R | 1 |
| Pasek, M | 1 |
| Ho, V | 1 |
| Soiffer, R | 1 |
| Alyea, E | 1 |
| Kline, J | 1 |
| Nathanson, J | 1 |
| Noffsinger, A | 1 |
| Artz, A | 1 |
| Tfayli, A | 1 |
| Selby, G | 1 |
| Maqbool, F | 1 |
| Bierbaum, W | 1 |
| Tauchmanovà, L | 1 |
| Alviggi, C | 1 |
| Foresta, C | 1 |
| Strina, I | 1 |
| Garolla, A | 1 |
| Colao, A | 1 |
| Lombardi, G | 1 |
| De Placido, G | 1 |
| Rotoli, B | 1 |
| Selleri, C | 1 |
| Sari, I | 1 |
| Altuntas, F | 1 |
| Kocyigit, I | 1 |
| Sisman, Y | 1 |
| Eser, B | 1 |
| Unal, A | 2 |
| Fen, T | 1 |
| Ferahbas, A | 1 |
| Ozturk, A | 1 |
| Cetin, M | 1 |
| Cruickshank, S | 1 |
| Rodell, TC | 1 |
| Gooley, T | 3 |
| Schuening, F | 1 |
| Rowley, S | 2 |
| David, D | 1 |
| Brunvand, M | 1 |
| Berryman, B | 1 |
| Bouvier, M | 2 |
| Yamanoha, A | 1 |
| Nagasaki, A | 1 |
| Nakachi, S | 1 |
| Kinjo, S | 1 |
| Takasu, N | 1 |
| Habib, S | 1 |
| Nalesnik, MA | 1 |
| Ahmad, J | 1 |
| BuchBarker, D | 1 |
| Shakil, AO | 1 |
| Zhang, YZ | 1 |
| Gao, CJ | 1 |
| Zhang, BL | 1 |
| DA, WM | 1 |
| Han, XP | 1 |
| Li, HH | 1 |
| Jing, Y | 1 |
| Huang, WR | 1 |
| Bo, J | 1 |
| Wang, SH | 1 |
| Zhu, HY | 1 |
| Jin, HJ | 1 |
| Yu, L | 1 |
| Nagatoshi, Y | 1 |
| Hatano, M | 1 |
| Isomura, N | 1 |
| Sakiyama, M | 1 |
| Remlinger, K | 1 |
| Doney, KC | 3 |
| Smith, A | 1 |
| Sullivan, K | 1 |
| Thomas, ED | 3 |
| Wick, MR | 1 |
| Moore, SB | 1 |
| Gastineau, DA | 3 |
| Hoagland, HC | 1 |
| Cohen, DJ | 1 |
| Loertscher, R | 1 |
| Rubin, MF | 1 |
| Tilney, NL | 1 |
| Carpenter, CB | 1 |
| Strom, TB | 1 |
| Westberg, MW | 1 |
| Burns, CP | 1 |
| Klassen, LW | 1 |
| Goeken, NE | 1 |
| Ray, TL | 1 |
| Macfarlane, DE | 1 |
| Nikoskelainen, J | 1 |
| Söderström, KO | 1 |
| Rajamäki, A | 1 |
| Meurman, L | 1 |
| Korvenranta, H | 1 |
| Kalliomäki, JL | 1 |
| Toivanen, A | 1 |
| Parker, PM | 3 |
| Chao, N | 1 |
| Nademanee, A | 3 |
| O'Donnell, MR | 6 |
| Schmidt, GM | 4 |
| Snyder, DS | 6 |
| Stein, AS | 3 |
| Smith, EP | 4 |
| Molina, A | 4 |
| Stepan, DE | 3 |
| Kashyap, A | 3 |
| Planas, I | 2 |
| Spielberger, R | 3 |
| Somlo, G | 1 |
| Margolin, K | 1 |
| Zwingenberger, K | 1 |
| Wilsman, K | 1 |
| Long, GD | 4 |
| Niland, JC | 5 |
| Forman, SJ | 6 |
| Parker, P | 3 |
| Dagis, AC | 3 |
| Stein, A | 2 |
| O'Donnell, M | 1 |
| Anderson, KC | 1 |
| Adams, GB | 1 |
| Jamal, N | 1 |
| Liedtke, W | 1 |
| Quabeck, K | 1 |
| Beelen, DW | 1 |
| Straeten, V | 1 |
| Schaefer, UW | 1 |
| Sélimi, F | 1 |
| Sedel, L | 1 |
| Frija, J | 1 |
| Devergie, A | 1 |
| Esperou Bourdeau, H | 1 |
| Gluckman, E | 2 |
| Hings, IM | 2 |
| Severson, R | 1 |
| Filipovich, AH | 5 |
| Kersey, JH | 5 |
| McGlave, PB | 4 |
| Kohli-Kumar, M | 1 |
| Morris, C | 1 |
| DeLaat, C | 1 |
| Sambrano, J | 1 |
| Masterson, M | 1 |
| Mueller, R | 1 |
| Shahidi, NT | 1 |
| Yanik, G | 1 |
| Desantes, K | 1 |
| Friedman, DJ | 1 |
| Fussell, ST | 1 |
| Donnellan, M | 1 |
| Cooley, MA | 1 |
| Farrell, C | 1 |
| Miller, WJ | 3 |
| Blazar, BL | 1 |
| Nemunaitis, J | 2 |
| Bianco, JA | 2 |
| Hasen, J | 1 |
| Singer, JW | 2 |
| Fries, BC | 1 |
| Khaira, D | 1 |
| Pepe, MS | 2 |
| Torok-Storb, B | 1 |
| Amylon, MD | 3 |
| Nademanee, AP | 4 |
| Baehr, PH | 1 |
| Levine, DS | 2 |
| Bouvier, ME | 1 |
| Stern, JG | 1 |
| Pirenne, J | 1 |
| Gruessner, A | 1 |
| Benedetti, E | 1 |
| Moon, C | 1 |
| Troppmann, C | 1 |
| Nakhleh, RE | 1 |
| Gruessner, RW | 1 |
| D'Angelo, P | 1 |
| Rizzari, C | 1 |
| Jankovic, M | 1 |
| Dampier, C | 1 |
| Masera, G | 1 |
| Johnson, FL | 1 |
| Chesnut, CH | 1 |
| Bruemmer, B | 1 |
| Sullivan, KM | 6 |
| Lenssen, PS | 1 |
| Sanders, J | 1 |
| Ben-Ezra, J | 1 |
| Slatkin, N | 1 |
| Openshaw, H | 1 |
| Linker, CA | 1 |
| Greffe, BS | 1 |
| Sheibani, K | 1 |
| Bensinger, WI | 3 |
| Buckner, CD | 5 |
| Shannon-Dorcy, K | 1 |
| Benyunes, M | 1 |
| Clift, R | 1 |
| Demirer, T | 1 |
| Lee, M | 1 |
| Schiller, G | 1 |
| Parkes, IR | 1 |
| Zaki, I | 1 |
| Stevens, A | 1 |
| Davies, JM | 1 |
| Allen, BR | 1 |
| Kingreen, D | 1 |
| Nitsche, A | 1 |
| Beyer, J | 1 |
| Siegert, W | 1 |
| Ferrà, C | 2 |
| de Sanjosé, S | 1 |
| Lastra, CF | 1 |
| Martí, F | 1 |
| Mariño, EL | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Gallardo, D | 2 |
| Berlanga, JJ | 1 |
| García, J | 1 |
| Grañena, A | 2 |
| Ko, CW | 1 |
| Myerson, D | 1 |
| Hackman, RC | 2 |
| Shulman, HM | 3 |
| Sale, GE | 1 |
| Lee, SP | 1 |
| Farrand, A | 1 |
| Murakami, C | 1 |
| Tzung, SP | 1 |
| Schiffman, K | 1 |
| Ross, M | 1 |
| Wong, RM | 2 |
| Jain, M | 1 |
| Hu, WW | 1 |
| Tierney, DK | 1 |
| Fung, H | 1 |
| Kohler, S | 1 |
| Krishnan, A | 1 |
| Rodriguez, R | 1 |
| Bluzme, KG | 1 |
| Saunders, MD | 1 |
| Murakami, CS | 1 |
| Gelly, KJ | 1 |
| Kerr, R | 1 |
| Rawlinson, S | 1 |
| Norris, A | 1 |
| Bowen, DT | 1 |
| Cragg, L | 1 |
| Defor, T | 2 |
| Kolatker, N | 1 |
| Miller, W | 2 |
| Kersey, J | 2 |
| Ramsay, M | 1 |
| McGlave, P | 4 |
| Filipovich, A | 1 |
| Koc, S | 2 |
| Witherspoon, RP | 4 |
| Strasser, SI | 1 |
| Reddy, R | 1 |
| Margolis, DA | 1 |
| Prumbaum, M | 1 |
| Seropian, SE | 1 |
| Hovi, L | 1 |
| Saarinen-Pihkala, UM | 1 |
| Vettenranta, K | 1 |
| Saxen, H | 1 |
| Fassas, AB | 1 |
| Rapoport, AP | 1 |
| Cottler-Fox, M | 1 |
| Chen, T | 1 |
| Tricot, G | 1 |
| Malik, AH | 1 |
| Collins, RH | 1 |
| Saboorian, MH | 1 |
| Lee, WM | 1 |
| Enright, H | 2 |
| Weisdorf, DF | 1 |
| Nagler, A | 1 |
| Menachem, Y | 1 |
| Ilan, Y | 1 |
| Feinstein, L | 1 |
| Sandmaier, B | 1 |
| Maloney, D | 1 |
| McSweeney, PA | 1 |
| Maris, M | 1 |
| Flowers, C | 1 |
| Radich, J | 1 |
| Little, MT | 1 |
| Chauncey, T | 1 |
| Georges, G | 1 |
| Zaucha, JM | 1 |
| Shizuru, J | 1 |
| Ancín, I | 1 |
| Peris, J | 1 |
| Berlanga, J | 1 |
| Gonzalez, JR | 1 |
| Virgili, N | 1 |
| Abu-Elmagd, K | 1 |
| Reyes, J | 1 |
| Bond, G | 1 |
| Mazariegos, G | 1 |
| Wu, T | 1 |
| Murase, N | 1 |
| Sindhi, R | 1 |
| Martin, D | 1 |
| Colangelo, J | 1 |
| Zak, M | 1 |
| Janson, D | 1 |
| Ezzelarab, M | 1 |
| Dvorchik, I | 1 |
| Parizhskaya, M | 1 |
| Deutsch, M | 1 |
| Demetris, A | 1 |
| Fung, J | 1 |
| Starzl, TE | 1 |
| Kumar, S | 2 |
| Chen, MG | 2 |
| Gertz, MA | 2 |
| Inwards, DJ | 2 |
| Lacy, MQ | 2 |
| Tefferi, A | 2 |
| Harmsen, WS | 1 |
| França, CM | 1 |
| Domingues-Martins, M | 1 |
| Volpe, A | 1 |
| Pallotta Filho, RS | 1 |
| Soares de Araújo, N | 1 |
| Kang, EM | 1 |
| de Witte, M | 1 |
| Malech, H | 1 |
| Morgan, RA | 1 |
| Phang, S | 1 |
| Carter, C | 1 |
| Leitman, SF | 1 |
| Barrett, AJ | 1 |
| Little, R | 1 |
| Tisdale, JF | 1 |
| Menillo, SA | 1 |
| McKiernan, P | 1 |
| Pecora, AL | 1 |
| Le Blanc, R | 1 |
| Montminy-Métivier, S | 1 |
| Bélanger, R | 1 |
| Busque, L | 1 |
| Fish, D | 1 |
| Roy, DC | 1 |
| Kassis, J | 1 |
| Boileau, J | 1 |
| Lavallée, R | 1 |
| Bélanger, D | 1 |
| Letendre, F | 1 |
| Hébert, J | 1 |
| Sauvageau, G | 1 |
| Perreault, C | 1 |
| Roy, J | 2 |
| Oyama, Y | 1 |
| Papadopoulos, EB | 1 |
| Miranda, M | 1 |
| Traynor, AE | 1 |
| Burt, RK | 1 |
| Nagarajan, R | 1 |
| Neglia, J | 1 |
| Ramsay, N | 2 |
| Baker, KS | 1 |
| Witherspoon, R | 2 |
| Thompson, D | 1 |
| Thirman, MJ | 1 |
| Devine, SM | 1 |
| O'Toole, K | 1 |
| Cizek, G | 1 |
| Jessurun, J | 1 |
| Hertz, M | 1 |
| Geller, RB | 1 |
| Burger, J | 1 |
| Gmür, J | 1 |
| Bruckner-Tuderman, L | 1 |
| Valbonesi, M | 1 |
| Occhini, D | 1 |
| Frisoni, R | 1 |
| Malfanti, L | 1 |
| Capra, C | 1 |
| Gualandi, F | 1 |
| Dopfer, R | 1 |
| Henze, G | 1 |
| Bender-Götze, C | 1 |
| Ebell, W | 1 |
| Ehninger, G | 1 |
| Friedrich, W | 1 |
| Gadner, H | 1 |
| Klingebiel, T | 1 |
| Peters, C | 1 |
| Riehm, H | 1 |
| Higano, CS | 1 |
| Mori, M | 1 |
| Bianco, J | 1 |
| Epstein, C | 1 |
| Lipani, J | 1 |
| Hansen, J | 1 |
| Frappaz, D | 1 |
| Souillet, G | 1 |
| Maraninchi, D | 1 |
| Demeocq, F | 1 |
| Fischer, A | 1 |
| Lutz, P | 1 |
| Bergerat, JP | 1 |
| Herve, P | 1 |
| Freycon, F | 1 |
| Pepe, M | 1 |
| Beatty, P | 3 |
| Stewart, P | 2 |
| Clift, RA | 2 |
| Bearman, SI | 1 |
| Petersen, FB | 1 |
| Fisher, LD | 1 |
| Haake, R | 2 |
| Ash, R | 1 |
| Hows, JM | 1 |
| Higano, C | 1 |
| Applebaum, FR | 1 |
| Neiman, PE | 1 |
| Atkinson, K | 1 |
| Bryant, D | 1 |
| Delprado, W | 1 |
| Biggs, J | 1 |
| Piantadosi, S | 1 |
| Farmer, ER | 1 |
| Jabs, DA | 1 |
| Levin, LS | 1 |
| Beschorner, WE | 1 |
| Cahill, RA | 1 |
| Miller, DF | 1 |
| Harrison, D | 1 |
| Conde, E | 1 |
| Iriondo, A | 1 |
| Richard, C | 1 |
| Garijo, J | 1 |
| Hermosa, V | 1 |
| Pastor, JM | 1 |
| Cuadrado, MA | 1 |
| Recio, M | 1 |
| Bureo, E | 1 |
| Bello, C | 1 |
| Clark, J | 1 |
| Meyers, J | 1 |
| Sale, G | 1 |
| Hess, AD | 1 |
| Friedman, KJ | 1 |
| Santos, GW | 2 |
| Weiden, P | 2 |
| Flournoy, N | 1 |
| Dahlberg, S | 2 |
| Krance, RA | 2 |
| Miner, PJ | 1 |
| Metter, GE | 1 |
| Hill, LR | 2 |
| Arthur, DC | 1 |
| Kim, T | 2 |
| Shukla, LW | 1 |
| Katz, JA | 1 |
| Wagner, ML | 1 |
| Arthur, D | 1 |
| Hurd, D | 1 |
| Vercellotti, G | 1 |
| Greenberg, A | 1 |
| Egel, JW | 1 |
| Thompson, ME | 1 |
| Hardesty, RL | 1 |
| Griffith, BP | 1 |
| Bahnson, HT | 1 |
| Bernstein, RL | 1 |
| Hastillo, A | 1 |
| Hess, ML | 1 |
| Puschett, JB | 1 |
| First, LR | 1 |
| Smith, BR | 1 |
| Nathan, DG | 1 |
| Parkman, R | 1 |
| Rappeport, JM | 1 |
| Trigg, ME | 1 |
| Billing, R | 1 |
| Sondel, PM | 1 |
| Exten, R | 1 |
| Hong, R | 1 |
| Bozdech, MJ | 1 |
| Horowitz, SD | 1 |
| Finlay, JL | 1 |
| Moen, R | 1 |
| Longo, W | 1 |
| Krawczak, CL | 1 |
| Goldman, A | 1 |
| Goldstein, G | 1 |
| Henke, M | 1 |
| Findley, DO | 1 |
| Sensenbrenner, LL | 1 |
| Burke, PJ | 1 |
| Mullins, GM | 1 |
| Anderson, PN | 1 |
| Tutschka, PJ | 1 |
| Braine, HG | 1 |
| Davis, TE | 1 |
| Humphrey, RL | 1 |
| Abeloff, MD | 1 |
| Bias, WB | 1 |
| Borgaonkar, DS | 1 |
| Slavin, RE | 1 |
| Kline, TS | 1 |
| Craighead, JE | 1 |
| Laerum, OD | 1 |
| Flatmark, L | 1 |
| Enge, I | 1 |
| Westlie, L | 1 |
| Kolb, HJ | 1 |
| Graham, TC | 1 |
| Kolb, H | 1 |
| Weiden, PL | 1 |
| Enger, E | 1 |
| Bergan, F | 1 |
| Hoeg, K | 1 |
| Malm, OJ | 1 |
| Thorsby, E | 1 |
| Levitt, SH | 1 |
| Royster, RL | 1 |
| O'Foughludha, FT | 1 |
| Wolf, JS | 1 |
| Lower, RR | 1 |
| King, ER | 1 |
| DeGiorgi, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease[NCT01680965] | Phase 1/Phase 2 | 44 participants (Actual) | Interventional | 2012-11-14 | Completed | ||
| A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN 1501)[NCT02806947] | Phase 2 | 127 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Improving Outcomes Assessment in Chronic GVHD[NCT00637689] | 601 participants (Actual) | Observational | 2007-09-30 | Active, not recruiting | |||
| A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)[NCT01954979] | Phase 1 | 22 participants (Anticipated) | Interventional | 2013-10-31 | Active, not recruiting | ||
| A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)[NCT01002742] | Phase 3 | 236 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase II Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease[NCT00702689] | Phase 2 | 20 participants (Actual) | Interventional | 2008-12-15 | Completed | ||
| L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis[NCT02631109] | Phase 3 | 120 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Study of the Function of Immune System in Patients Undergoing Allogeneic Stem Cell Transplantation[NCT03233659] | 177 participants (Actual) | Observational | 2014-08-12 | Completed | |||
| A Pilot Study of Early Treatment of Acute Graft Versus Host Disease With Bone Marrow- Derived Mesenchymal Stem Cells and Corticosteroids: Correlation of Disease Severity and Response With Biomarkers[NCT02379442] | Phase 1/Phase 2 | 1 participants (Actual) | Interventional | 2015-02-23 | Terminated | ||
| Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease[NCT01161628] | Phase 2 | 25 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease[NCT06046248] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease[NCT00136396] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
| Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastroin[NCT00926575] | Phase 3 | 140 participants (Actual) | Interventional | 2009-10-31 | Terminated (stopped due to An independent Data Safety Monitoring Board recommended the study be stopped due to futility) | ||
| Phase I Dose Escalation of T-cell Receptor α/β Depleted Donor Lymphocyte Infusions Following CD34+- Selected Allogeneic Stem Cell Transplantation From Related & Unrelated Donors in Patients With Lymphoid, Myeloid or Plasma Cell Malignancies[NCT05350163] | Phase 1 | 11 participants (Actual) | Interventional | 2022-04-05 | Active, not recruiting | ||
| A Randomized, Placebo-Controlled, Multi-Center Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal Graft Vs. Host Disease[NCT00233896] | Phase 3 | 130 participants | Interventional | 2001-07-31 | Completed | ||
| Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients With Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning With Campath- 1H or h-ATG, Radiation, and Sirolimus[NCT00426517] | Early Phase 1 | 48 participants (Actual) | Interventional | 2007-01-19 | Completed | ||
| An Investigator Initiated Open Study to Evaluate the Efficacy and Safety of Intra Arterial Infusion for Treatment of Steroid Resistant Acute Hepatic Graft Versus Host Disease (AGVHD)[NCT01140984] | 2 participants (Actual) | Interventional | 2010-09-30 | Terminated (stopped due to technical issues) | |||
| Treatment of Chronic Graft Versus Host Disease With Extracorporeal Photopheresis[NCT00048789] | Phase 2 | 25 participants | Interventional | 2002-11-04 | Completed | ||
| Azacitidine (AZA) Combined With N-Acetyl-L-cysteine (NAC) for Prolonged Isolated Thrombocytopenia (PIT) After Hematopoietic Stem Cell Transplantation (HSCT)[NCT05126004] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-12-01 | Not yet recruiting | ||
| A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation[NCT02487563] | Phase 3 | 97 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maximum Tolerated Dose was determined by increasing doses, beginning at 300 mg on day 0 and day 14, then increasing to 700 mg on day 0 and day 14 and finally 1000 mg on day 0 and day 14. (NCT01680965)
Timeframe: within 21 days of initiation
| Intervention | mg (Number) |
|---|---|
| Phase 1: All Participants | 1000 |
Overall Survival is defined as the time period from start of treatment to death. (NCT01680965)
Timeframe: Up to 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab | 74.4 |
Overall response rate (ORR) at 6 months following initiation of therapy. ORR is the composite outcome of complete response and partial response (NCT01680965)
Timeframe: 6 months following initiation of Ofatumumab
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab | 62.5 |
Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification. The cumulative incidence of chronic GVHD is described, with death and malignancy relapse treated as competing risks. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Chronic GVHD at 6 Months | Chronic GVHD at 12 Months | |
| Prednisone | 31.2 | 40.6 |
| Sirolimus | 25.7 | 31.4 |
Disease-free survival is defined as freedom from death and relapse of the underlying malignancy. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Disease-free Survival at 6 Months | Disease-free Survival at 12 Months | |
| Prednisone | 78.1 | 70.2 |
| Sirolimus | 72.8 | 61.6 |
GVHD-free survival is defined as freedom from acute GVHD, chronic GVHD, and death. The proportion of participants alive and free of both acute and chronic GVHD are described at 6 and 12 months post-randomization. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| GVHD-free Survival at 6 Months | GVHD-free Survival at 12 Months | |
| Prednisone | 46.0 | 46.0 |
| Sirolimus | 45.3 | 50.9 |
The cumulative incidence of relapse of the primary malignancy is described, with death treated as a competing risk. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Malignancy Relapse at 6 Months | Malignancy Relapse at 12 Months | |
| Prednisone | 12.5 | 15.7 |
| Sirolimus | 14.5 | 21.9 |
Non-relapse mortality is defined as death due to any cause other than relapse of the underlying malignancy. The cumulative incidence of non-relapse mortality is described, with malignancy relapse treated as a competing risk. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Non-relapse Mortality at 6 Months | Non-relapse Mortality at 12 Months | |
| Prednisone | 9.4 | 14.2 |
| Sirolimus | 12.7 | 16.5 |
Overall survival is defined as survival of death from any cause. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Overall Survival at 6 Months | Overall Survival at 12 Months | |
| Prednisone | 82.7 | 73.2 |
| Sirolimus | 81.9 | 76.3 |
The cumulative incidence of serious infections (Grade 2 or 3 per BMT CTN MOP) is described, with death treated as a competing risk. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Seirious Infections at 6 Months | Seirious Infections at 12 Months | |
| Prednisone | 43.8 | 51.8 |
| Sirolimus | 30.4 | 39.6 |
Event-free survival is defined as freedom from acute GVHD progression, chronic GVHD, malignancy relapse, and death. (NCT02806947)
Timeframe: 6 and 12 Months Post-randomization
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Event-free Survival at 6 Months | Event-free Survival at 12 Months | |
| Prednisone | 43.7 | 31.2 |
| Sirolimus | 47.3 | 35.9 |
"Acute GVHD response is classified as CR, PR, mixed response (MR), no response (NR), and progression and scored by comparison to acute GVHD status at randomization. MR is defined as improvement in some organ(s) with worsening in another, progression as worsening in some organ(s) without improvement in others, and NR as absence of any improvement or worsening. Death and initiation of systemic acute GVHD treatment beyond randomized treatment are classified as NR. Organ staging is defined as:~Skin stage:~0: No rash~Rash <25% of body surface area (BSA)~Rash 25-50% of BSA~Rash >50% of BSA~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level in mg/dL):~0: <2~2-3~3.01-6~6.01-15.0~>15~GI stage:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus" (NCT02806947)
Timeframe: Days 28 and 56 Post-randomization
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute GVHD Response at Day 2872566669 | Acute GVHD Response at Day 2872566668 | Acute GVHD Response at Day 5672566669 | Acute GVHD Response at Day 5672566668 | |||||||||||||||||
| Complete Response (CR) | Partial Response (PR) | Mixed Response (MR) | No Response (NR) | Progression | ||||||||||||||||
| Prednisone | 39 | |||||||||||||||||||
| Sirolimus | 5 | |||||||||||||||||||
| Prednisone | 7 | |||||||||||||||||||
| Sirolimus | 1 | |||||||||||||||||||
| Prednisone | 5 | |||||||||||||||||||
| Sirolimus | 16 | |||||||||||||||||||
| Prednisone | 11 | |||||||||||||||||||
| Sirolimus | 2 | |||||||||||||||||||
| Prednisone | 1 | |||||||||||||||||||
| Sirolimus | 30 | |||||||||||||||||||
| Prednisone | 48 | |||||||||||||||||||
| Sirolimus | 4 | |||||||||||||||||||
| Prednisone | 2 | |||||||||||||||||||
| Sirolimus | 0 | |||||||||||||||||||
| Prednisone | 0 | |||||||||||||||||||
| Sirolimus | 19 | |||||||||||||||||||
| Prednisone | 10 | |||||||||||||||||||
| Prednisone | 3 | |||||||||||||||||||
"Scoring of CR/PR is in comparison to the participant's acute GVHD status at randomization. Complete response (CR) is defined as staging of 0 for in all target organs for GVHD - skin, GI tract, and liver. Partial response (PR) is defined as improvement in some target organ(s) without worsening in others. Death and initiation of systemic acute GVHD treatment beyond randomized treatment are considered failures for this endpoint. Organ staging is defined below:~Skin stage:~0: No rash~Rash <25% of body surface area (BSA)~Rash on 25-50% of BSA~Rash on >50% of BSA~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level):~0: <2 mg/dL~2-3 mg/dL~3.01-6 mg/dL~6.01-15.0 mg/dL~>15 mg/dL~GI stage:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus" (NCT02806947)
Timeframe: Days 28 and 56 Post-randomization
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| CR/PR at Day 2872566668 | CR/PR at Day 2872566669 | CR/PR at Day 5672566669 | CR/PR at Day 5672566668 | |||||
| Yes | No | |||||||
| Sirolimus | 35 | |||||||
| Prednisone | 46 | |||||||
| Prednisone | 17 | |||||||
| Sirolimus | 34 | |||||||
| Prednisone | 50 | |||||||
| Sirolimus | 19 | |||||||
| Prednisone | 13 | |||||||
"Treatment failure is defined as either no response (NR) or progression and scored by comparison to acute GVHD status at randomization. Progression is defined as worsening in some target organ(s) without improvement in others and NR is defined as absence of any improvement or worsening in target organs. Death and initiation of systemic acute GVHD treatment beyond randomized treatment are classified as NR. Organ staging is defined as:~Skin stage:~0: No rash~Rash <25% of body surface area (BSA)~Rash 25-50% of BSA~Rash >50% of BSA~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level in mg/dL):~0: <2~2-3~3.01-6~6.01-15.0~>15~GI stage:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus" (NCT02806947)
Timeframe: Days 28 and 56 Post-randomization
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Treatment Failure at Day 2872566668 | Treatment Failure at Day 2872566669 | Treatment Failure at Day 5672566668 | Treatment Failure at Day 5672566669 | |||||
| No | Yes | |||||||
| Sirolimus | 18 | |||||||
| Prednisone | 12 | |||||||
| Sirolimus | 36 | |||||||
| Prednisone | 51 | |||||||
| Sirolimus | 19 | |||||||
| Prednisone | 13 | |||||||
| Sirolimus | 34 | |||||||
| Prednisone | 50 | |||||||
(NCT01002742)
Timeframe: Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 42.9 |
| Mycophenolate Mofetil | 44.5 |
DFS includes death or progression/relapse of malignancy (NCT01002742)
Timeframe: Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 63 |
| Mycophenolate Mofetil | 53.9 |
(NCT01002742)
Timeframe: 12 months post-randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 43.3 |
| Mycophenolate Mofetil | 41.5 |
(NCT01002742)
Timeframe: Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 39 |
| Mycophenolate Mofetil | 44 |
(NCT01002742)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Placebo | 4 |
| Mycophenolate Mofetil | 6 |
Flares are defined as any progression of acute GVHD after an initial response (i.e., earlier CR or PR) that requires re-escalation of steroid dosing, or initiation of additional topical or systemic therapy. (NCT01002742)
Timeframe: Day 90
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Mycophenolate Mofetil | 8 |
Number of participants that experienced at least one infection. (NCT01002742)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Placebo | 77 |
| Mycophenolate Mofetil | 81 |
(NCT01002742)
Timeframe: Day 56
| Intervention | participants (Number) |
|---|---|
| Placebo | 81 |
| Mycophenolate Mofetil | 77 |
(NCT01002742)
Timeframe: Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 21.5 |
| Mycophenolate Mofetil | 21.8 |
The cumulative steroid dose for each patient will be calculated by adding the doses (end of each week's dose) for each of the first four weeks of treatment, divided by the number of days of survival during this interval. The cumulative steroid dose was calculated for all patients per treatment arm and compared. (NCT01002742)
Timeframe: Days 28 and 56
| Intervention | mg/kg (Number) | |
|---|---|---|
| Day 28 | Day 56 | |
| Mycophenolate Mofetil | 0.60 | 0.17 |
| Placebo | 0.63 | 0.20 |
Success is defined as alive and free of GVHD at day 56 after randomization, all others are considered to be a study failure. (NCT01002742)
Timeframe: Day 56
| Intervention | participants (Number) | |
|---|---|---|
| GVHD free | Study Failure | |
| Mycophenolate Mofetil | 69 | 47 |
| Placebo | 60 | 59 |
(NCT01002742)
Timeframe: Months 6 and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 Months | 12 Months | |
| Mycophenolate Mofetil | 72.0 | 57.8 |
| Placebo | 73.4 | 64.7 |
CR is defined as a score of 0 for the GVHD grading in all evaluable organs. (NCT01002742)
Timeframe: Days 14, 28, and 56
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 14 | Day 28 | Day 56 | |
| Mycophenolate Mofetil | 44 | 46.6 | 60.3 |
| Placebo | 49.6 | 44.5 | 53.8 |
One or more joints were assessed for ROM deficit by a physiatrist with expertise in graft versus host disease and joint ROM. (NCT00702689)
Timeframe: 6 months
| Intervention | Percent change (Mean) |
|---|---|
| Imatinib Mesylate in Patients With cGVHD | 24.2 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00702689)
Timeframe: Date treatment consent signed to date off study, approximately, 41 months, 27 days
| Intervention | Participants (Number) |
|---|---|
| Imatinib Mesylate in Patients With cGVHD | 20 |
Change in immunosuppression was defined by an increase or decrease in steroid use form baseline. (NCT00702689)
Timeframe: 6 months
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ↓ Pred 20 mg everyday (qd )to 5 mg every other day | ↓ MPred 16 mg every other day(qod) to 4 mg qod | ↓ Pred:24mg every day(qd) to 20mg qd | No change | ↓ Tacro 2mg every am 1.5mg every pm to .5mg bid | Pred↓ 25mg qd to 15mg qd;Tacro↓ 2mg bid to 1mg bid | Pred↓ 2.5mg qd to 2.5mg every other day | ↓ Siro:2mg qd to 1 mg qd | Pred wean then ↑ 10 12.5mg bid;Tacro↑1.0 to 1.5bid | MMF↓ 1g/bid to discontinued | |
| Imatinib Mesylate in Patients With cGVHD | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 1 |
Lung function was graded by the National Institutes of Health Chronic Graft Versus Host Disease organ response criteria. The Lung function score = forced expiratory volume 1 (FEV1) score + carbon monoxide diffusing capacity (DLCO) score, with a possible range of 2 (better outcome)-12 (worst outcome). The percent predicted FEV1 and DLCO (adjusted for hematocrit but not alveolar volume) should be converted to a numeric score as follows: >80% =1; 70-79% = 2; 60-69% = 3; 50-59% = 4; 40-49% = 5; <40% = 6. (NCT00702689)
Timeframe: Baseline and 6 Months
| Intervention | units on a scale (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #2 at Baseline | Patient #2 at 6 Months | Patient #3 at Baseline | Patient #3 at 6 Months | Patient #7 at Baseline | Patient #7 at 6 Months | Patient #8 at Baseline | Patient #8 at 6 Months | Patient #10 at Baseline | Patient #10 at 6 Months | Patient #12 at Baseline | Patient #12 at 6 Months | Patient #13 at Baseline | Patient #13 at 6 Months | Patient #14 at Baseline | Patient #14 at 6 Months | Patient # 15 at Baseline | Patient #15 at 6 Months | Patient #16 at Baseline | Patient #16 at 6 Months | Patient #17 at Baseline | Patient #17 at 6 months | Patient #18 at Baseline | Patient #18 at 6 Months | Patient #19 at Baseline | Patient #19 at 6 Months | Patient #20 at Baseline | Patient #20 at 6 Months | |
| Imatinib Mesylate in Patients With cGVHD | 2 | 2 | 9 | NA | 3 | 8 | 5 | 6 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 5 | 7 | 6 | 3 | 2 | 5 | 6 | 8 | 8 | 9 | 9 | 2 | 2 |
A change in ROM is 25% or greater from baseline. A partial response required improvement in 25% or more in ROM. Progression required 25% or greater loss of ROM.Patients with negative values in the Table are those who lost ROM. Percent improvement in ROM for 1-3 target joints. For patients with >1 target joint, the average ROM improvement was calculated. The average percentage change in ROM deficit from baseline to 6 months was obtained based on the number of degrees of ROM change (6 months)/total ROM deficit (baseline) at each joint. (NCT00702689)
Timeframe: 6 months
| Intervention | Percent change from baseline (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 2 6mo response% change in deficit from baseline | Pt 7 6mo response% change in deficit from baseline | Pt 8 6mo response% change in deficit from baseline | Pt10 6mo response% change in deficit from baseline | Pt12 6mo response% change in deficit from baseline | Pt13 6mo response% change in deficit from baseline | Pt14 6mo response% change in deficit from baseline | Pt15 6mo response% change in deficit from baseline | Pt16 6mo response% change in deficit from baseline | Pt17 6mo response% change in deficit from baseline | Pt18 6mo response% change in deficit from baseline | Pt19 6mo response% change in deficit from baseline | Pt20 6mo response% change in deficit from baseline | |
| Imatinib Mesylate in Patients With cGVHD | 94 | 35 | 16 | 21 | 16 | 61 | 27 | 22 | 3 | -25 | -2 | 31 | 15 |
Progressive disease is defined as joint ROM: decrease of >25% in composite ROM score on 2 consecutive evaluations at least 2 weeks apart, but not greater than 4 weeks apart or steroid pulse: >1 steroid pulse per 3 month period if administered for sclerotic-type chronic graft versus host disease (ScGVHD). Response is joint ROM: increase of >25% in composite ROM score. Maximal response is a response with no further improvement over 2 sequential 3-month evaluations. Stable disease does not meet the criteria for progression, response, or maximal response. (NCT00702689)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Partial Response | Stable Disease | Progressive Disease | |
| Imatinib Mesylate in Patients With cGVHD | 5 | 7 | 2 |
The provider global rating is a physician impression of severity of cGVHD symptoms from a scale of zero (no symptoms) to 10 (most severe GVHD symptoms possible). (NCT00702689)
Timeframe: Baseline and 6 months
| Intervention | Provider Global Rating Score (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #2 at Baseline | Patient #2 at 6 Months | Patient #3 at Baseline | Patient #3 at 6 Months | Patient #7 at Baseline | Patient #7 at 6 Months | Patient #8 at Baseline | Patient #8 at 6 Months | Patient #10 at Baseline | Patient #10 at 6 Months | Patient #12 at Baseline | Patient #12 at 6 Months | Patient #13 at Baseline | Patient #13 at 6 Months | Patient #14 at Baseline | Patient #14 at 6 Months | Patient # 15 at Baseline | Patient #15 at 6 Months | Patient #16 at Baseline | Patient #16 at 6 Months | Patient #17 at Baseline | Patient #17 at 6 months | Patient #18 at Baseline | Patient #18 at 6 Months | Patient #19 at Baseline | Patient #19 at 6 Months | Patient #20 at Baseline | Patient #20 at 6 Months | |
| Imatinib Mesylate in Patients With cGVHD | 5 | 4 | 3 | NA | 6 | 8 | 6 | 7 | 5 | 4 | 6 | 7 | 6 | 4 | 7 | 6 | 7 | 6 | 5 | 4 | 6 | 8 | 8 | 8 | 8 | 5 | 8 | 8 |
Total skin score was graded by the National Institutes of Health Consensus Criteria. Skin score was calculated by dividing the total score by seven domains (skin, eye, oral, joint, gastrointestinal, hepatic, pulmonary) in men and 8 domains in women (previous domains noted plus gynecologic). Total skin score is a percentage of body surface area (BSA) involvement (range 0-100%). It was calculated from the sum of moveable body surface BSA and non-moveable BSA. Higher numbers = greater body surface area affected. (NCT00702689)
Timeframe: Baseline and 6 Months
| Intervention | units on a scale (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient # 2 - Baseline | Patient # 2 - 6 months | Patient # 3 - Baseline | Patient # 3 - 6 months | Patient # 7 - Baseline | Patient # 7 - 6 months | Patient # 8 - Baseline | Patient # 8 - 6 months | Patient # 10 - Baseline | Patient # 10 - 6 months | Patient # 12 - Baseline | Patient # 12 - 6 months | Patient # 13 - Baseline | Patient # 13 - 6 months | Patient # 14 - Baseline | Patient # 14 - 6 months | Patient # 15 - Baseline | Patient # 15 - 6 months | Patient # 16 - Baseline | Patient # 16 - 6 months | Patient # 17 - Baseline | Patient # 17 - 6 months | Patient # 18 - Baseline | Patient # 18 - 6 months | Patient # 19 - Baseline | Patient # 19 - 6 months | Patient # 20 - Baseline | Patient # 20 - 6 months | |
| Imatinib Mesylate in Patients With cGVHD | 66.6 | 54 | 43.38 | NA | 66.24 | 55.53 | 53.1 | 55.26 | 10.8 | 6.12 | 21.24 | 30.06 | 79.2 | 62.28 | 39.96 | 40.5 | 71.46 | 61.83 | 9.54 | 8.1 | 84.96 | 85.11 | 26.64 | 24.3 | 21.15 | 37.8 | 23.4 | 25.2 |
The number of subjects without a treatment related severe adverse event (TRSAE) within 56 days of treatment. (NCT02379442)
Timeframe: 56 days
| Intervention | Participants (Count of Participants) |
|---|---|
| BMSC | 1 |
(NCT01161628)
Timeframe: 2 years
| Intervention | days (Median) |
|---|---|
| Rituxan | 15 |
(NCT01161628)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Rituxan | 79 |
(NCT01161628)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Rituxan | 21 |
(NCT01161628)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Rituxan | 82 |
(NCT01161628)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Rituxan | 84 |
(NCT01161628)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Rituxan | 88 |
(NCT01161628)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Rituxan | 5 |
(NCT01161628)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Rituxan | 20 |
(NCT01161628)
Timeframe: 2 years
| Intervention | days (Median) |
|---|---|
| Rituxan | 300 |
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib Plus Rituximab | 0 |
Recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 109 /L (500/mm3 ) for three consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of three consecutive laboratory values where the ANC is ≥ 0.5 x 109 /L. (NCT00426517)
Timeframe: 1 year
| Intervention | Days (Mean) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 19.42 |
| Matched Unrelated Donor Stem Cell Transplant | 77.44 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 25.5 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | NA |
Rapidity of immune reconstitution based on number of days to CD3 count greater than 100 u/L. (NCT00426517)
Timeframe: 1 year
| Intervention | Days (Mean) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 355 |
| Matched Unrelated Donor Stem Cell Transplant | 284 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 16 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | NA |
Platelet recovery is defined as platelet value ≥ 20 × 109/L for three consecutive days and no platelet transfusions administered for previous seven consecutive days. The date of platelet recovery is the date of the first of three consecutive laboratory values ≥ 20 × 109/L. (NCT00426517)
Timeframe: 1 year
| Intervention | Days (Mean) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 31 |
| Matched Unrelated Donor Stem Cell Transplant | 31.9 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 32.6 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | NA |
Participants who achieved engraftment without development of graft versus host disease (GVHD). (NCT00426517)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 6 |
| Matched Unrelated Donor Stem Cell Transplant | 30 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 3 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | NA |
Number of events of Cytomegalovirus disease based on clinical sequelae that requires treatment (not reactivation) (NCT00426517)
Timeframe: 1 year
| Intervention | Number of events (Mean) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 0 |
| Matched Unrelated Donor Stem Cell Transplant | 0 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 0 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | 0 |
Average number of red blood cell (RBC) transfusion per subject (NCT00426517)
Timeframe: 1 year
| Intervention | transfusions per person (Mean) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 1.71 |
| Matched Unrelated Donor Stem Cell Transplant | 7.08 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 4 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | NA |
Number of participants with myeloid chimerism of greater than 10% of donor cells at 1 year post transplant (NCT00426517)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 7 |
| Matched Unrelated Donor Stem Cell Transplant | 30 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 3 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | NA |
Engraftment of allogeneic or matched unrelated (including cord blood) hematopoietic progenitor cells using moderate-dose busulfan and Campath-1H with or without whole body irradiation so as to attain phenotypic correction of congenital immunodeficiencies. (NCT00426517)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Matched Related Donor Stem Cell Transplant | 7 |
| Matched Unrelated Donor Stem Cell Transplant | 31 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | 3 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | 0 |
The total number of megakaryocytes as well as the platelet-shedding megakaryocytes of bone marrow smears (per cm2) was counted and cross-checked by blinded observers. (NCT02487563)
Timeframe: Up to 4 weeks after the treatment
| Intervention | cells/cm^2 (Median) |
|---|---|
| Experimental Group 1 | 6.7 |
| Experimental Group 2 | 7.5 |
| Control Group | 3.3 |
Platelet response refers to a sustained increase (stable or increasing level) of at least 30×10E9/L independent of transfusion for 3 days. (NCT02487563)
Timeframe: Up to 4 weeks after the treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Group 1 | 20 |
| Experimental Group 2 | 22 |
| Control Group | 6 |
15 reviews available for prednisone and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Child; Disease Progression; Drug Resistan | 2020 |
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.
Topics: Glucocorticoids; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppr | 2012 |
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colony-Stimulating Factors; Cyclophospham | 2012 |
[Chronic graft versus host disease (GvHD): causes, manifestation, diagnosis and treatment option].
Topics: Anti-Inflammatory Agents; Chronic Disease; Glucocorticoids; Graft vs Host Disease; Humans; Prednison | 2012 |
Steroid-refractory graft-vs.-host disease: past, present and future.
Topics: Acute Disease; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chi | 2003 |
Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Topics: Acute Disease; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2007 |
Immunologic, clinical, and pathologic aspects of human graft-versus-host disease.
Topics: Aged; Biopsy; Bone Marrow Transplantation; Drug Therapy, Combination; Globulins; Graft vs Host Disea | 1983 |
Cyclosporine: a new immunosuppressive agent for organ transplantation.
Topics: Animals; Azathioprine; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Cyclospo | 1984 |
Polymyositis as a manifestation of chronic graft-versus-host disease.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Bone Marrow Transplantation; Ch | 1996 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; | 2001 |
Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 2001 |
Allogeneic stem cell transplantation for Evans syndrome.
Topics: Adrenal Cortex Hormones; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Autoimmune Di | 2001 |
Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation.
Topics: Bone Marrow; Cladribine; Combined Modality Therapy; Cyclosporine; Cytarabine; Doxorubicin; Drug Ther | 2001 |
[Allogenic bone marrow graft in thalassemia major. The French experience].
Topics: Adolescent; Blood Transfusion; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporins; F | 1990 |
Long-term complications of bone marrow transplantation.
Topics: Azathioprine; Bone Marrow Transplantation; Chronic Disease; Graft vs Host Disease; Humans; Prednison | 1989 |
42 trials available for prednisone and Graft-Versus-Host Disease
| Article | Year |
|---|---|
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.
Topics: Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Graft vs Host Disease; Humans; Immunos | 2022 |
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
Topics: Bronchiolitis Obliterans Syndrome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
Topics: Bronchiolitis Obliterans Syndrome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
Topics: Bronchiolitis Obliterans Syndrome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
Topics: Bronchiolitis Obliterans Syndrome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal | 2020 |
Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2021 |
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.
Topics: Adult; Aged; Calcineurin Inhibitors; Chronic Disease; Disease Progression; Endpoint Determination; F | 2017 |
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Topics: Abatacept; Adult; Aged; Chronic Disease; Cohort Studies; Female; Glucocorticoids; Graft vs Host Dise | 2018 |
The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group.
Topics: Adult; Aged; Beclomethasone; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Drug | 2014 |
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cohort Studies; Fema | 2014 |
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Bone Marrow Transplantation; Child; | 2014 |
Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Exanthema; Female; Follow-Up Studie | 2015 |
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Drug Administration Schedule; Fasciitis; Female; Gr | 2015 |
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chron | 2015 |
Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, Neoplasm; Biomarkers; Child; Child, Preschool; Cyc | 2015 |
PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cisplatin; D | 2016 |
The best endpoint for acute GVHD treatment trials.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Female; Glucocorticoids; Graft vs Host Disease; | 2010 |
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
Topics: Chronic Disease; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2011 |
What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Di | 2012 |
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
Topics: Adult; Calcineurin Inhibitors; Cause of Death; Chronic Disease; Creatinine; Drug Therapy, Combinatio | 2005 |
Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; D | 2005 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
Rituximab for steroid-refractory chronic graft-versus-host disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas | 2006 |
A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Beclomethasone; Child; Fema | 2007 |
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine; | 1995 |
Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graf | 1993 |
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distrib | 1993 |
Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Beclomethasone; Graft v | 1995 |
Bone density loss during treatment of chronic GVHD.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Marrow Transplantation; Cyclosporine; Diet; Female | 1996 |
Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy.
Topics: Adult; Aged; Antigens, CD34; Blood Cells; Cell Count; Cell Separation; Cyclophosphamide; Cyclosporin | 1996 |
Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Bone Marro | 1997 |
Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Beclomethasone; Female; Graft vs Host Disease; Humans; Inflammato | 1998 |
Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Beclomethasone; Female; Graft vs Host Disease; Humans; Inflammato | 1998 |
Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Beclomethasone; Female; Graft vs Host Disease; Humans; Inflammato | 1998 |
Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Beclomethasone; Female; Graft vs Host Disease; Humans; Inflammato | 1998 |
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Bone Marrow Transplantation; Cause of De | 1999 |
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Bone Marrow Transplantation; Child; Chil | 2000 |
A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Antilymphocyte Serum; Bone Marrow Transp | 2000 |
Thalidomide for treatment of patients with chronic graft-versus-host disease.
Topics: Actuarial Analysis; Chronic Disease; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; G | 2000 |
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
Topics: Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Graft vs Host | 2001 |
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Cyclosporine; Drug Administration Sched | 2002 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1991 |
Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; | 1991 |
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
Topics: Acute Disease; Anemia, Aplastic; Bone Marrow Transplantation; Chronic Disease; Clinical Trials as To | 1990 |
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporins; Female; Graft | 1990 |
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disea | 1988 |
A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Cyclosporins; Drug Therapy, Combination; Graft vs | 1987 |
Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Child; Child, Preschool; Clinical | 1985 |
143 other studies available for prednisone and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival.
Topics: Calcineurin Inhibitors; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Pred | 2021 |
A single low-dose rituximab infusion in severe chronic refractory myasthenia gravis in resource-limited settings.
Topics: Autoantibodies; Graft vs Host Disease; Humans; Immunologic Factors; Myasthenia Gravis; Prednisone; R | 2022 |
Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failure.
Topics: Bronchiolitis Obliterans Syndrome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD.
Topics: Adrenal Cortex Hormones; Bronchiolitis Obliterans Syndrome; Graft vs Host Disease; Humans; Photopher | 2023 |
Simultaneous Determination of Prednisone and Prednisolone in Serum by Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Graft vs Host Disease; Humans; Prednis | 2024 |
Pediatric acute GVHD: clinical phenotype and response to upfront steroids.
Topics: Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Phenotype; Prednisone | 2020 |
A Case of Nephrotic Syndrome after Allogeneic Stem Cell Transplantation.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents; Diuretics; Graft vs Host Disease; Hematopoietic Stem | 2020 |
Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Penile Diseases | 2020 |
Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2018 |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease- | 2017 |
Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bronchiolitis Obliterans; Female; Forced Expiratory Volume; G | 2017 |
The Rare Complication and Diagnostic Challenges of Pulmonary Eosinophilia in Graft versus Host Disease Patients after Hematopoietic Stem Cell Transplantation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Chronic Disease; Diagn | 2017 |
Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment.
Topics: Adult; Aged; Azathioprine; Canada; Chronic Disease; Drug Therapy, Combination; Female; Graft vs Host | 2018 |
Periorbital lupuslike presentation of graft-versus-host disease.
Topics: Aged; Anti-Inflammatory Agents; Biopsy; Dendritic Cells; Eyelid Diseases; Graft vs Host Disease; Hem | 2018 |
Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease.
Topics: Adult; Chronic Disease; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2018 |
Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2013 |
DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.
Topics: Aged; Antiviral Agents; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2014 |
Scurvy: a new problem for patients with chronic GVHD involving mucous membranes; an easy problem to resolve.
Topics: Administration, Oral; Adolescent; Adult; Ascorbic Acid; Ascorbic Acid Deficiency; Child; Chronic Dis | 2014 |
Successful treatment of non-Hodgkin's lymphoma using R-CHOP in a patient with Wiskott-Aldrich syndrome followed by a reduced-intensity stem cell transplant.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Possible amlodipine-induced hepatotoxicity after stem cell transplant.
Topics: Aged; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Aspartate Aminotransferases; Chemic | 2015 |
The end of knight-errantry in GVHD studies.
Topics: Adrenal Cortex Hormones; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Immunos | 2014 |
Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Antilymphocyte Serum; Dose-Response Relationship, Dr | 2015 |
Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Glucocorticoids; Graft vs Host Dis | 2015 |
Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Fol | 2015 |
Pressure-induced isomorphic sclerodermoid graft-versus-host disease from brassiere underwire and tight-fitting watch.
Topics: Aged; Anti-Inflammatory Agents; Clothing; Female; Graft vs Host Disease; Humans; Jewelry; Prednisone | 2015 |
Case report: An unusual presentation of oral acute graft-versus-host-disease in a haploidentical hematopoietic stem cell transplant recipient.
Topics: Adolescent; Glucocorticoids; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2016 |
[Analysis of Risk Factors for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation].
Topics: Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2016 |
Cutaneous phaeohyphomycosis in a hematopoietic stem cell transplant patient caused by Alternaria rosae: First case report.
Topics: Acute Kidney Injury; Acyclovir; Aged; Alternaria; Alternariosis; Antibiotic Prophylaxis; Antifungal | 2017 |
Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease.
Topics: Adult; Anti-Inflammatory Agents; Antigen-Presenting Cells; B7-2 Antigen; Bone Marrow; Case-Control S | 2008 |
Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide | 2008 |
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.
Topics: Acute Disease; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Glucocorticoids; G | 2009 |
[Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
Topics: Acute Disease; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Drug Resistance; Drug Therapy, C | 2008 |
Erythema multiforme-like presentation of chronic graft versus host disease.
Topics: Erythema Multiforme; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; M | 2008 |
[A case of chronic graft-versus-host disease presenting with polymyositis].
Topics: Bone Marrow Transplantation; Female; Glucocorticoids; Graft vs Host Disease; Humans; Lymphoma, T-Cel | 2009 |
Chronic GVHD manifesting as parotitis after allogeneic hematopoietic SCT.
Topics: Adult; Anemia, Aplastic; Anti-Inflammatory Agents; Diagnosis, Differential; Female; Graft vs Host Di | 2009 |
Polymyositis and myocarditis after donor lymphocyte infusion.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Blood Donors; Chronic Disease; Female; Graft vs | 2009 |
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.
Topics: Acute Disease; Adult; Aged; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2010 |
[Sustained molecular remission in an adult patient with Sézary syndrome after peripheral allogeneic stem-cell transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Fema | 2011 |
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Topics: Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppr | 2010 |
Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes.
Topics: Acute Disease; Adult; Aged; Blood Glucose; Cohort Studies; Diabetes Complications; Drug Monitoring; | 2011 |
Clinical-pathological conference: case 2.
Topics: Adult; Bone Marrow Transplantation; Chronic Disease; Diagnosis, Differential; Female; Gingivitis, Ne | 2010 |
Effect of splenectomy on pancytopenia after a peripheral blood stem cell transplantation.
Topics: Adult; Busulfan; Cyclophosphamide; Dexamethasone; Female; Graft Survival; Graft vs Host Disease; Hem | 2011 |
Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract.
Topics: Animals; Bone Marrow Transplantation; Cell Adhesion Molecules; Chemokines; Cytokines; Disease Models | 2011 |
Cervical and vaginal cancer in a woman with chronic graft-versus-host disease.
Topics: Biopsy; Bone Marrow Transplantation; Carcinoma, Squamous Cell; Chronic Disease; Female; Graft vs Hos | 2011 |
Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Bronchiolitis Obliterans; Bronchodilator | 2011 |
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation.
Topics: Adult; Aged; Combined Modality Therapy; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoiet | 2011 |
Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease.
Topics: Adolescent; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2011 |
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 2013 |
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Child; Child, Preschoo | 2013 |
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Female; Graft v | 2002 |
Acute graft-versus-host disease of the lung after liver transplantation.
Topics: Acute Disease; Administration, Oral; Aged; Bronchitis; Drug Administration Schedule; Female; Glucoco | 2002 |
Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease.
Topics: Adult; Bone Marrow Transplantation; Chronic Disease; Combined Modality Therapy; Female; Graft vs Hos | 2002 |
Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2002 |
Treating refractory chronic graft-versus-host disease with extracorporeal photochemotherapy.
Topics: Adult; Chronic Disease; Cyclosporine; Ficusin; Graft vs Host Disease; Histocompatibility Testing; Hu | 2003 |
Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cyclosporine; Graft vs Host | 2003 |
THE TREATMENT OF CHRONIC MURINE HOMOLOGOUS DISEASE: A COMPARATIVE STUDY OF FOUR "IMMUNOSUPPRESSIVE" AGENTS.
Topics: Animals; Antigens; Cachexia; Graft vs Host Disease; Immunosuppressive Agents; Mercaptopurine; Methot | 1965 |
Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.
Topics: Adult; Bone Marrow Diseases; Bone Marrow Transplantation; Brain; Calcineurin Inhibitors; Central Ner | 2003 |
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2003 |
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation.
Topics: Adolescent; Adult; Bronchiolitis Obliterans; Case-Control Studies; Cryptogenic Organizing Pneumonia; | 2004 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclospo | 2004 |
Steroid-sparing effect of extracorporeal photopheresis in the treatment of graft-vs-host disease.
Topics: Cyclosporine; Drug Administration Schedule; Graft vs Host Disease; Humans; Immunosuppressive Agents; | 2004 |
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Cohort Studies; Female; Graft vs | 2004 |
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Cohort Studies; Female; Graft vs | 2004 |
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Cohort Studies; Female; Graft vs | 2004 |
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Cohort Studies; Female; Graft vs | 2004 |
Microscopic polyangiitis sparing the kidneys in a long-term survivor after allogeneic bone marrow transplantation and graft-versus-host disease.
Topics: Antibodies, Antineutrophil Cytoplasmic; Bone Marrow Transplantation; Cyclophosphamide; Drug Therapy, | 2005 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Drug Administratio | 2005 |
Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease.
Topics: Adult; Aged; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Graft vs Host Dise | 2005 |
Late effects of chronic graft-vs.-host disease in minor salivary glands.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Biopsy; Bone Marrow Transplantation; Case-Control Studi | 2005 |
Membranous glomerulopathy in children given allogeneic hematopoietic stem cell transplantation.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 2005 |
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.
Topics: Adult; Anti-Inflammatory Agents; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematopoi | 2006 |
Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Stud | 2006 |
Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers.
Topics: Adolescent; Adult; Age Factors; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Fem | 2006 |
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.
Topics: Acute Disease; Adolescent; Adult; Algorithms; Bilirubin; Child; Child, Preschool; Graft vs Host Dise | 2006 |
Severe intestinal graft-versus-host disease following autologous stem cell transplantation.
Topics: Diarrhea; Female; Graft vs Host Disease; Humans; Intestinal Diseases; Middle Aged; Prednisone; Stem | 2006 |
Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease.
Topics: Administration, Oral; Antineoplastic Agents; Diarrhea; Diphtheria Toxin; Drug Resistance; Female; Ga | 2006 |
Cryptozoospermia with normal testicular function after allogeneic stem cell transplantation: a case report.
Topics: Adult; Azoospermia; Biopsy, Fine-Needle; Graft vs Host Disease; Hematopoietic Stem Cell Transplantat | 2007 |
The effect of budesonide mouthwash on oral chronic graft versus host disease.
Topics: Adult; Budesonide; Candidiasis, Oral; Chronic Disease; Cohort Studies; Cyclosporine; Drug Evaluation | 2007 |
Air-leak syndrome associated with bronchiolitis obliterans after allogeneic peripheral blood stem cell transplantation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Bronchiolitis Obliterans; Cyclosporine; Cytomegalovi | 2007 |
Alloimmune hepatitis following peripheral stem cell transplantation.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Busulfan; Cyclophosphamide; Female; Graft vs Host Dis | 2007 |
[Late-onset noninfectious pulmonary complications after allogeneic peripheral blood stem cell transplantation].
Topics: Adolescent; Adult; Cyclosporine; Female; Graft vs Host Disease; Humans; Incidence; Leukemia; Lung Di | 2007 |
Rash and GI symptoms on day +36.
Topics: Adult; Cytomegalovirus Infections; Diarrhea; Exanthema; Glucocorticoids; Graft vs Host Disease; Huma | 2007 |
Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Chronic Disease; Drug Therapy, Combination; Fema | 2008 |
Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease.
Topics: Acute Disease; Adolescent; Adult; Antibodies, Monoclonal; Bone Marrow Transplantation; Child; Combin | 1984 |
Acute graft-versus-host disease resulting from normal donor blood transfusions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Histocompatibi | 1984 |
Graft-versus-host reaction in 3 adult leukaemia patients after transfusion of blood cell products.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubic | 1983 |
The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclosporine; Female; Graft Survival; Graft vs Host | 1995 |
Who benefits from high-dose therapy for multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Gr | 1995 |
Allogeneic bone marrow transplantation from a related donor undergoing long-term immunosuppressive and cytotoxic therapy.
Topics: Antineoplastic Agents; Azathioprine; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; Cy | 1994 |
Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Demyelinating Dise | 1994 |
Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Anemia, Aplastic; Bone Marrow Transplantation; Child; | 1994 |
Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, P | 1994 |
Bone marrow transplantation in Fanconi anemia using matched sibling donors.
Topics: Abdomen; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Cy | 1994 |
Cytotoxic T lymphocyte precursor frequency does not correlate with either the incidence or severity of graft-versus-host disease after matched unrelated donor bone marrow transplantation.
Topics: Bone Marrow Transplantation; Cyclosporine; Graft Survival; Graft vs Host Disease; Humans; Incidence; | 1994 |
rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Child, Preschool; Cross | 1993 |
Declining lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant patients.
Topics: Adult; Bone Marrow Transplantation; Cytomegalovirus Infections; Dexamethasone; Female; Graft vs Host | 1993 |
Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs.
Topics: Animals; Autopsy; Colon; Death; Graft Rejection; Graft vs Host Disease; Immunosuppressive Agents; In | 1996 |
High-dose cytosine arabinoside and fractionated total body irradiation as a preparative regimen for the treatment of children with acute lymphoblastic leukemia and Down syndrome by allogeneic bone marrow transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Pres | 1996 |
Post-transplantation complications of unrelated bone marrow.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Immunosuppr | 1996 |
Graft-versus-host disease-like eruption in a patient with non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Graft vs Host Disease; Human | 1997 |
Herpes simplex infection of the jejunum occurring in the early post-transplantation period.
Topics: Adult; Anti-Inflammatory Agents; Bone Marrow Transplantation; Diagnosis, Differential; DNA, Viral; E | 1997 |
Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis.
Topics: Abdominal Pain; Acute Disease; Adult; Amylases; Bile; Biomarkers; Bone Marrow Transplantation; Cause | 1997 |
Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Diagnosis, Differential; Female; Gastritis; Graft vs Host Disease; Hematopoietic Stem C | 1998 |
Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation.
Topics: Acute Disease; Alkaline Phosphatase; Apoptosis; Bile Ducts, Intrahepatic; Cholestasis; Epithelial Ce | 2000 |
Transfusion-associated graft vs. host disease in a patient with high-grade B-cell lymphoma. Should cellular products for patients with non-Hodgkin's lymphoma be irradiated?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Graft vs Host Disease | 2000 |
Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis.
Topics: Acute Disease; Adult; Chronic Disease; Cyclosporine; Diagnosis, Differential; Drug Therapy, Combinat | 2000 |
Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Antifungal Agents; Bone Marrow Transplantation; | 2000 |
Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Female; Follow-Up Studies; Glucocorticoids; Graft | 2000 |
Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis.
Topics: Acute Disease; Adult; Biopsy; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transp | 2001 |
Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment.
Topics: Adolescent; Adult; Cholestasis, Intrahepatic; Cyclosporine; Drug Evaluation; Drug Resistance; Female | 2001 |
Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2001 |
Clinical intestinal transplantation: a decade of experience at a single center.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Cyclophos | 2001 |
Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Topics: Adolescent; Adult; Cause of Death; Child; Child, Preschool; Chronic Disease; Cyclosporine; Disease-F | 2001 |
Severe oral manifestations of chronic graft-vs.-host disease.
Topics: Adult; Anemia, Aplastic; Anti-Inflammatory Agents; Betamethasone; Bone Marrow Transplantation; Chron | 2001 |
Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Contraindications; Female; | 2001 |
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Anti-Bacterial Agents; Antiretroviral Ther | 2002 |
Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation.
Topics: Adult; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hu | 2001 |
Antibody and pre- plus post-transplant prednisone treatments support T cell-depleted stem cell engraftment without drug-induced morbidity.
Topics: Animals; Antibodies, Monoclonal; Bone Marrow Transplantation; CD28 Antigens; CD4 Antigens; Drug Admi | 2002 |
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
Topics: Acute Disease; Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow Transplanta | 2002 |
Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Bronchiolitis Obliterans; Graft vs Host Disease; Humans; Leukemi | 1992 |
Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Female; Graft vs Host Disea | 1992 |
Epidermolysis bullosa acquisita, a rare late complication of allogeneic bone marrow transplantation?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantat | 1992 |
Cyclosporin-induced hypertriglyceridemia with prompt response to plasma exchange therapy.
Topics: Adolescent; Bezafibrate; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Femal | 1991 |
Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Child; Child, Preschool; Confidence Int | 1990 |
Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporins; Drug Combinat | 1990 |
Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients.
Topics: Bone Marrow Transplantation; Duodenoscopy; Endoscopy; Esophagoscopy; Gastroscopy; Graft vs Host Dise | 1990 |
Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combi | 1985 |
Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease.
Topics: Adult; Anemia, Aplastic; Bone Marrow Transplantation; Cyclosporins; Diagnosis, Differential; Graft v | 1989 |
Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Analysis of Variance; Azathioprine; Bone Marrow Transplantati | 1989 |
[Prevention of acute graft versus host disease using 3 prophylactic schemes].
Topics: Acute Disease; Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transpla | 1989 |
Therapy of chronic graft-v-host disease in a rat model.
Topics: Animals; Azathioprine; Cyclosporins; Disease Models, Animal; Drug Synergism; Graft vs Host Disease; | 1989 |
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Cyclospori | 1988 |
Allogeneic bone marrow transplantation with related donors other than HLA MLC-matched siblings, and the use of antithymocyte globulin, prednisone, and methotrexate for prophylaxis of graft-versus-host disease.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Femal | 1985 |
Mediastinal lipomatosis: a complication of high dose steroid therapy in children.
Topics: Child; Graft vs Host Disease; Humans; Lipomatosis; Male; Mediastinal Neoplasms; Prednisone | 1988 |
Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation.
Topics: Antigens, Surface; Antilymphocyte Serum; Bone Marrow Transplantation; Cyclophosphamide; Graft vs Hos | 1987 |
Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients.
Topics: Acute Kidney Injury; Adult; Azathioprine; beta 2-Microglobulin; Cardiopulmonary Bypass; Cyclosporins | 1987 |
Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.
Topics: Actuarial Analysis; Adolescent; Adult; Azathioprine; Bone Marrow; Bone Marrow Transplantation; Child | 1985 |
Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.
Topics: Actuarial Analysis; Adolescent; Adult; Azathioprine; Bone Marrow; Bone Marrow Transplantation; Child | 1985 |
Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.
Topics: Actuarial Analysis; Adolescent; Adult; Azathioprine; Bone Marrow; Bone Marrow Transplantation; Child | 1985 |
Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.
Topics: Actuarial Analysis; Adolescent; Adult; Azathioprine; Bone Marrow; Bone Marrow Transplantation; Child | 1985 |
Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transplantation; Child; | 1985 |
Bone marrow transplantation for acute leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporins; Follow-Up Stu | 1985 |
Allogeneic marrow grafts in man using cyclophosphamide.
Topics: Amidines; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; | 1974 |
Renal homotransplantation. The cytology of the urine sediment.
Topics: Adrenal Cortex Hormones; Azaserine; Azathioprine; Cytomegalovirus Infections; Dactinomycin; Graft vs | 1967 |
Pneumocystis carinii pneumonia in Norway.
Topics: Adult; Autopsy; Female; Graft vs Host Disease; Humans; Immunity, Cellular; Immunologic Deficiency Sy | 1972 |
Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone.
Topics: Animals; Antilymphocyte Serum; Blood Cell Count; Blood Platelets; Bone Marrow Cells; Bone Marrow Tra | 1973 |
[Kidney transplantation at Ullevål hospital. A 7 year material].
Topics: Adult; Antigens; Corticosterone; Creatinine; Female; Follow-Up Studies; Graft vs Host Disease; Human | 1971 |
Radiation for immunosuppression in human organ transplantation. II. Clinical experience.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Azathioprine; Blood; Cadaver; Child; Dogs; Extraco | 1971 |